{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:21:03Z","timestamp":1791231663017,"version":"4.1.0"},"reference-count":368,"publisher":"Japanese Circulation Society","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ J"],"published-print":{"date-parts":[[2020,1,24]]},"DOI":"10.1253\/circj.cj-19-0773","type":"journal-article","created":{"date-parts":[[2020,1,17]],"date-time":"2020-01-17T17:05:25Z","timestamp":1579280725000},"page":"299-359","source":"Crossref","is-referenced-by-count":106,"title":["JCS 2017 Guideline on Management of Vasculitis Syndrome\u3000\u2015 Digest Version \u2015"],"prefix":"10.1253","volume":"84","author":[{"given":"Mitsuaki","family":"Isobe","sequence":"first","affiliation":[{"name":"Sakakibara Heart Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Amano","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Arimura","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Nephrology, Kyorin University School of Medicine"},{"name":"Internal Medicine, Kichijoji Asahi Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Ishizu","sequence":"additional","affiliation":[{"name":"Department of Medical Laboratory Science, Faculty of Health Sciences, Hokkaido University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichi","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Graduate School of Medicine, Yokohama City University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Kaname","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Rheumatology, Kyorin University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeto","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Juntendo Koshigaya Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Komagata","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Rheumatology, Kyorin University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Issei","family":"Komuro","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, The University of Tokyo Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimihiro","family":"Komori","sequence":"additional","affiliation":[{"name":"Division of Vascular Surgery, Department of Surgery, Nagoya University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Pathology, Toho University Ohashi Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Tanemoto","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Surgery, Kawasaki Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Hasegawa","sequence":"additional","affiliation":[{"name":"Department of Hematology, Clinical Immunology, and Infectious Diseases, Ehime University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayoshi","family":"Harigai","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, School of Medicine, Tokyo Women\u2019s Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shouichi","family":"Fujimoto","sequence":"additional","affiliation":[{"name":"Department of Hemovascular Medicine and Artificial Organs, Faculty of Medicine, University of Miyazaki"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuhiko","family":"Miyazaki","sequence":"additional","affiliation":[{"name":"Department of Pathology, Gifu University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuro","family":"Miyata","sequence":"additional","affiliation":[{"name":"Vascular Center, Sanno Hospital and Sanno Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidehiro","family":"Yamada","sequence":"additional","affiliation":[{"name":"Medical Center for Rheumatic Diseases, Seirei Yokohama Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akitoshi","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Asahikawa Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Wada","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Laboratory Medicine, Graduate School of Medical Sciences, Kanazawa University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Inoue","sequence":"additional","affiliation":[{"name":"Ambulatory Vascular Surgical Clinic Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruhito A.","family":"Uchida","sequence":"additional","affiliation":[{"name":"Department of Chronic Kidney Disease and Cardiovascular Disease, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Ota","sequence":"additional","affiliation":[{"name":"Department of Advanced MRI Collaboration Research, Tohoku University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Okazaki","sequence":"additional","affiliation":[{"name":"Vice-Director, Shizuoka Medical Center, National Hospital Organization"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuho","family":"Onimaru","sequence":"additional","affiliation":[{"name":"Division of Pathophysiological and Experimental Pathology, Department of Pathology, Graduate School of Medical Sciences, Kyushu University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamihiro","family":"Kawakami","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Tohoku Medical and Pharmaceutical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reiko","family":"Kinouchi","sequence":"additional","affiliation":[{"name":"Medicine and Engineering Combined Research Institute, Asahikawa Medical University"},{"name":"Department of Ophthalmology, Asahikawa Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Kurata","sequence":"additional","affiliation":[{"name":"Department of Molecular Pathology, Tokyo Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisanori","family":"Kosuge","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Tokyo Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken-ei","family":"Sada","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunihiro","family":"Shigematsu","sequence":"additional","affiliation":[{"name":"Department of Vascular Surgery, International University of Health and Welfare Mita Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiichi","family":"Suematsu","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine and Rheumatology, National Hospital Organization, Kyushu Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eijun","family":"Sueyoshi","sequence":"additional","affiliation":[{"name":"Department of Radiological Science, Nagasaki University Graduate School of Biomedical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiko","family":"Sugihara","sequence":"additional","affiliation":[{"name":"Department of Lifetime Clinical Immunology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Sugiyama","sequence":"additional","affiliation":[{"name":"Department of Human Resource Development of Dialysis Therapy for Kidney Disease, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiro","family":"Takeno","sequence":"additional","affiliation":[{"name":"Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Tamura","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Rheumatology, Juntendo University Faculty of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michi","family":"Tsutsumino","sequence":"additional","affiliation":[{"name":"Institute of Rheumatology, Tokyo Women\u2019s Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Dobashi","sequence":"additional","affiliation":[{"name":"Division of Hematology, Rheumatology and Respiratory Medicine Department of Internal Medicine, Faculty of Medicine, Kagawa University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshikazu","family":"Nakaoka","sequence":"additional","affiliation":[{"name":"Department of Vascular Physiology, National Cerebral and Cardiovascular Center Research Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Nagasaka","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Ome Municipal General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Maejima","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Tokyo Medical and Dental University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Yoshifuji","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiko","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Frist Department of Physiology, Kawasaki Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoichi","family":"Ozaki","sequence":"additional","affiliation":[{"name":"Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kimura","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Shigematsu","sequence":"additional","affiliation":[{"name":"Clinical Research Center for Medicine, International University of Health and Welfare"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Yamauchi-Takihara","sequence":"additional","affiliation":[{"name":"Health and Counseling Center, Osaka University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toyoaki","family":"Murohara","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Nagoya University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin-ichi","family":"Momomura","sequence":"additional","affiliation":[{"name":"Saitama Medical Center Jichi Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the JCS Joint Working Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"330","reference":[{"key":"1","unstructured":"1. \u3000Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. <i>Arthritis Rheum<\/i> 2013; 65: 1\u201311. PMID: 23045170"},{"key":"2","unstructured":"2. \u3000Guideline for management of vasculitis syndrome (JCS 2008). <i>Circ J<\/i> 2008; 72 Suppl IV: 1253\u20131318. http:\/\/www.j-circ.or.jp\/guideline\/pdf\/JCS2008_ozaki_h.pdf"},{"key":"3","unstructured":"3. \u3000World Health Organization. WHO Handbook for Guideline Development \u2013 2nd Edition. 2014. http:\/\/apps.who.int\/medicinedocs\/documents\/s22083en\/s22083en.pdf"},{"key":"4","unstructured":"4. \u3000Fukui T, Yamaguchi N (ed.) Minds Handbook for the Preparation of Clinical Practice Guidelines 2014. Igaku-shoin Ltd. 2014. http:\/\/minds4.jcqhc.or.jp\/minds\/guideline\/handbook2014.html"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. \u3000Isobe M. Takayasu arteritis revisited: Current diagnosis and treatment. <i>Int J Cardiol<\/i> 2013; 168: 3\u201310. PMID: 23415176","DOI":"10.1016\/j.ijcard.2013.01.022"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. \u3000Ohigashi H, Haraguchi G, Konishi M, et al. Improved prognosis of Takayasu arteritis over the past decade: Comprehensive analysis of 106 patients. <i>Circ J<\/i> 2012; 76: 1004\u20131011. PMID: 22301847","DOI":"10.1253\/circj.CJ-11-1108"},{"key":"7","unstructured":"7. \u3000Takayasu M. Peculiar changes of the central retinal vessels. <i>Juzenkai Journal<\/i> 1908; 50: 1\u20134."},{"key":"8","unstructured":"8. \u3000Shimizu K, Sano K. Pulseless disease. <i>J Neuropathol Clin Neurol<\/i> 1951; 1: 37\u201347. PMID: 24538949"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. \u3000Ueda H, Saito Y, Ito I, et al. Immunological studies of aortitis syndrome. <i>Jpn Heart J<\/i> 1967; 8: 4\u201318.","DOI":"10.1536\/ihj.8.4"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. \u3000Ito I, Saito Y, Nonaka Y. Immunological aspects of aortitis syndrome. <i>Jpn Circ J<\/i> 1975; 39: 459\u2013462. PMID: 1121058","DOI":"10.1253\/jcj.39.459"},{"key":"11","unstructured":"11. \u3000Japan Intractable Diseases Information Center. Number of holders of certificates as recipients of medical benefit for specified diseases. http:\/\/www.nanbyou.or.jp\/entry\/1356"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. \u3000Watanabe Y, Miyata T, Tanemoto K. Current clinical Features of new patients with Takayasu arteritis observed from cross-country research in Japan: Age and sex specificity. <i>Circulation<\/i> 2015; 132: 1701\u20131709. PMID: 26354799","DOI":"10.1161\/CIRCULATIONAHA.114.012547"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. \u3000Hata A, Noda M, Moriwaki R, et al. Angiographic findings of Takayasu arteritis: New classification. <i>Int J Cardiol<\/i> 1996; 54 Suppl: S155\u2013S163. PMID: 9119518","DOI":"10.1016\/S0167-5273(96)02813-6"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. \u3000Isobe M. Current diagnosis and therapy of Takayasu arteritis. <i>J Jpn Soc Intern Med<\/i> 2014; 103: 2131\u20132136.","DOI":"10.2169\/naika.103.2131"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. \u3000Kato Y, Terashima M, Ohigashi H, et al. Vessel wall inflammation of Takayasu arteritis detected by contrast-enhanced magnetic resonance imaging: Association with disease distribution and activity. <i>PLoS One<\/i> 2015; 10: e0145855. PMID: 26720837","DOI":"10.1371\/journal.pone.0145855"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. \u3000Isohisa I, Numano F, Maezawa H, et al. HLA-Bw52 in Takayasu disease. <i>Tissue Antigens<\/i> 1978; 12: 246\u2013248. PMID: 31708","DOI":"10.1111\/j.1399-0039.1978.tb01332.x"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. \u3000Kimura A, Kitamura H, Date Y, et al. Comprehensive analysis of HLA genes in Takayasu arteritis in Japan. <i>Int J Cardiol<\/i> 1996; 54 Suppl: S61\u2013S69. PMID: 9119528","DOI":"10.1016\/S0167-5273(96)88774-2"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. \u3000Terao C, Yoshifuji H, Kimura A, et al. Two susceptibility loci to Takayasu arteritis reveal a synergistic role of the IL12B and HLA-B regions in a Japanese population. <i>Am J Hum Genet<\/i> 2013; 93: 289\u2013297. PMID: 23830516","DOI":"10.1016\/j.ajhg.2013.05.024"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. \u3000Hotchi M. Pathological studies on Takayasu arteritis. <i>Heart Vessels Suppl<\/i> 1992; 7: 11\u201317. PMID: 1360954","DOI":"10.1007\/BF01744538"},{"key":"20","unstructured":"20. \u3000Yutani C. Takayasu arteritis (aortitis syndrome), Volume of pathology. MHLW research project for conquering intractable diseases Study group on intractable vasculitides. <i>Vasculitis Atlas<\/i>2005: 7\u20138."},{"key":"21","unstructured":"21. \u3000Nasu T. Takayasu\u2019s truncoarteritis: Pulseless disease or aortitis syndrome. <i>Acta Pathol Jpn<\/i> 1982; 32 Suppl: 117\u2013131. PMID: 6139930"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. \u3000Jain D, Dietz HC, Oswald GL, et al. Causes and histopathology of ascending aortic disease in children and young adults. <i>Cardiovasc Pathol<\/i> 2011; 20: 15\u201325. PMID: 19926309","DOI":"10.1016\/j.carpath.2009.09.008"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. \u3000Takamura C, Ohhigashi H, Ebana Y, et al. New human leukocyte antigen risk allele in Japanese patients with Takayasu arteritis. <i>Circ J<\/i> 2012; 76: 1697\u20131702. PMID: 22664757","DOI":"10.1253\/circj.CJ-12-0089"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. \u3000Terao C, Yoshifuji H, Ohmura K, et al. Association of Takayasu arteritis with HLA-B 67:01 and two amino acids in HLA-B protein. <i>Rheumatology (Oxford)<\/i> 2013; 52: 1769\u20131774. PMID: 23873822","DOI":"10.1093\/rheumatology\/ket241"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. \u3000Hoffman GS, Ahmed AE. Surrogate markers of disease activity in patients with Takayasu arteritis: A preliminary report from The International Network for the Study of the Systemic Vasculitides (INSSYS). <i>Int J Cardiol<\/i> 1998; 66 Suppl: S191\u2013S194; discussion S195. PMID: 9951819","DOI":"10.1016\/S0167-5273(98)00181-8"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. \u3000Kerr GS. Takayasu\u2019s arteritis. <i>Rheum Dis Clin North Am<\/i> 1995; 21: 1041\u20131058. PMID: 8592736","DOI":"10.1016\/S0889-857X(21)00484-1"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. \u3000Koga T, Nishino Y, Makiyama J, et al. Serum amyloid A is a useful marker to evaluate the disease activity of Takayasu\u2019s arteritis. <i>Rheumatol Int<\/i> 2010; 30: 561\u2013563. PMID: 20020137","DOI":"10.1007\/s00296-009-1296-6"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. \u3000Ishihara T, Haraguchi G, Kamiishi T, et al. Sensitive assessment of activity of Takayasu\u2019s arteritis by pentraxin3, a new biomarker. <i>J Am Coll Cardiol<\/i> 2011; 57: 1712\u20131713. PMID: 21492771","DOI":"10.1016\/j.jacc.2010.10.058"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. \u3000Dagna L, Salvo F, Tiraboschi M, et al. Pentraxin-3 as a marker of disease activity in Takayasu arteritis. <i>Ann Intern Med<\/i> 2011; 155: 425\u2013433. PMID: 21969341","DOI":"10.7326\/0003-4819-155-7-201110040-00005"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. \u3000Tombetti E, Di Chio MC, Sartorelli S, et al. Systemic pentraxin-3 levels reflect vascular enhancement and progression in Takayasu arteritis. <i>Arthritis Res Ther<\/i> 2014; 16: 479. PMID: 25394473","DOI":"10.1186\/s13075-014-0479-z"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. \u3000Noris M, Daina E, Gamba S, et al. Interleukin-6 and RANTES in Takayasu arteritis: A guide for therapeutic decisions? <i>Circulation<\/i> 1999; 100: 55\u201360. PMID: 10393681","DOI":"10.1161\/01.CIR.100.1.55"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. \u3000Park MC, Lee SW, Park YB, et al. Serum cytokine profiles and their correlations with disease activity in Takayasu\u2019s arteritis. <i>Rheumatology (Oxford)<\/i> 2006; 45: 545\u2013548. PMID: 16352633","DOI":"10.1093\/rheumatology\/kei266"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. \u3000Mahajan N, Dhawan V, Malik S, et al. Serum levels of soluble receptor for advanced glycation end products (sRAGE) in Takayasu\u2019s arteritis. <i>Int J Cardiol<\/i> 2010; 145: 589\u2013591. PMID: 20579752","DOI":"10.1016\/j.ijcard.2010.05.075"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. \u3000Noguchi S, Numano F, Gravanis MB, et al. Increased levels of soluble forms of adhesion molecules in Takayasu arteritis. <i>Int J Cardiol<\/i> 1998; 66 Suppl: S23\u2013S33; discussion S35\u2013S36. PMID: 9951800","DOI":"10.1016\/S0167-5273(98)00145-4"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. \u3000Matsuyama A, Sakai N, Ishigami M, et al. Matrix metalloproteinases as novel disease markers in Takayasu arteritis. <i>Circulation<\/i> 2003; 108: 1469\u20131473. PMID: 12952836","DOI":"10.1161\/01.CIR.0000090689.69973.B1"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. \u3000Matsunaga N, Hayashi K, Sakamoto I, et al. Takayasu arteritis: Protean radiologic manifestations and diagnosis. <i>Radiographics<\/i> 1997; 17: 579\u2013594. PMID: 9153698","DOI":"10.1148\/radiographics.17.3.9153698"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. \u3000Zhu FP, Luo S, Wang ZJ, et al. Takayasu arteritis: Imaging spectrum at multidetector CT angiography. <i>Br J Radiol<\/i> 2012; 85: e1282\u2013e1292. PMID: 23175494","DOI":"10.1259\/bjr\/25536451"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. \u3000Yamada I, Nakagawa T, Himeno Y, et al. Takayasu arteritis: Evaluation of the thoracic aorta with CT angiography. <i>Radiology<\/i> 1998; 209: 103\u2013109. PMID: 9769819","DOI":"10.1148\/radiology.209.1.9769819"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. \u3000Yamada I, Nakagawa T, Himeno Y, et al. Takayasu arteritis: Diagnosis with breath-hold contrast-enhanced three-dimensional MR angiography. <i>J Magn Reson Imaging<\/i> 2000; 11: 481\u2013487. PMID: 10813857","DOI":"10.1002\/(SICI)1522-2586(200005)11:5<481::AID-JMRI3>3.0.CO;2-4"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. \u3000Li D, Lin J, Yan F. Detecting disease extent and activity of Takayasu arteritis using whole-body magnetic resonance angiography and vessel wall imaging as a 1-stop solution. <i>J Comput Assist Tomogr<\/i> 2011; 35: 468\u2013474. PMID: 21765303","DOI":"10.1097\/RCT.0b013e318222d698"},{"key":"41","unstructured":"41. \u3000Japan Radiological Society, Japanese College of Radiology. Guidelines for Imaging Diagnosis, 2013 edition. KANEHARA &amp; Co., LTD. 2013."},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. \u3000Mason JC. Takayasu arteritis: Advances in diagnosis and management. <i>Nat Rev Rheumatol<\/i> 2010; 6: 406\u2013415. PMID: 20596053","DOI":"10.1038\/nrrheum.2010.82"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. \u3000Isobe M. The Asia Pacific meeting on vasculitis and ANCA 2012 workshop on Takayasu arteritis: Advances in diagnosis and medical treatment. <i>Clin Exp Nephrol<\/i> 2013; 17: 686\u2013689. PMID: 24068578","DOI":"10.1007\/s10157-012-0697-0"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. \u3000Maeda H, Handa N, Matsumoto M, et al. Carotid lesions detected by B-mode ultrasonography in Takayasu\u2019s arteritis: \u201cMacaroni sign\u201d as an indicator of the disease. <i>Ultrasound Med Biol<\/i> 1991; 17: 695\u2013701. PMID: 1685816","DOI":"10.1016\/0301-5629(91)90101-2"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. \u3000Soussan M, Nicolas P, Schramm C, et al. Management of large-vessel vasculitis with FDG-PET: A systematic literature review and metaanalysis. <i>Medicine (Baltimore)<\/i> 2015; 94: e622. PMID: 25860208","DOI":"10.1097\/MD.0000000000000622"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. \u3000Cong XL, Dai SM, Feng X, et al. Takayasu\u2019s arteritis: Clinical features and outcomes of 125 patients in China. <i>Clin Rheumatol<\/i> 2010; 29: 973\u2013981. PMID: 20589520","DOI":"10.1007\/s10067-010-1496-1"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. \u3000Peter J, David S, Danda D, et al. Ocular manifestations of Takayasu arteritis: A cross-sectional study. <i>Retina<\/i> 2011; 31: 1170\u20131178. PMID: 21317836","DOI":"10.1097\/IAE.0b013e3181fe540b"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. \u3000Shelhamer JH, Volkman DJ, Parrillo JE, et al. Takayasu\u2019s arteritis and its therapy. <i>Ann Intern Med<\/i> 1985; 103: 121\u2013126. PMID: 2860834","DOI":"10.7326\/0003-4819-103-1-121"},{"key":"49","unstructured":"49. \u3000Bicakcigil M, Aksu K, Kamali S, et al. Takayasu\u2019s arteritis in Turkeyclinical and angiographic features of 248 patients. <i>Clin Exp Rheumatol<\/i> 2009; 27: S59\u2013S64. PMID: 19646348"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50. \u3000Freitas DS, Camargo CZ, Mariz HA, et al. Takayasu arteritis: Assessment of response to medical therapy based on clinical activity criteria and imaging techniques. <i>Rheumatol Int<\/i> 2012; 32: 703\u2013709. PMID: 21152919","DOI":"10.1007\/s00296-010-1694-9"},{"key":"51","doi-asserted-by":"crossref","unstructured":"50a. \u3000Kerr GS, Hallahan CW, Giordano J, et al. Takayasu arteritis. <i>Ann Intern Med<\/i> 1994; 120: 919\u2013929. PMID: 7909656","DOI":"10.7326\/0003-4819-120-11-199406010-00004"},{"key":"52","doi-asserted-by":"crossref","unstructured":"51. \u3000Maksimowicz-McKinnon K, Clark TM, Hoffman GS. Limitations of therapy and a guarded prognosis in an American cohort of Takayasu arteritis patients. <i>Arthritis Rheum<\/i> 2007; 56: 1000\u20131009. PMID: 17328078","DOI":"10.1002\/art.22404"},{"key":"53","doi-asserted-by":"crossref","unstructured":"52. \u3000Ozen S, Duzova A, Bakkaloglu A, et al. Takayasu arteritis in children: Preliminary experience with cyclophosphamide induction and corticosteroids followed by methotrexate. <i>J Pediatr<\/i> 2007; 150: 72\u201376. PMID: 17188618","DOI":"10.1016\/j.jpeds.2006.10.059"},{"key":"54","doi-asserted-by":"crossref","unstructured":"53. \u3000Ito I. Medical treatment of Takayasu arteritis. <i>Heart Vessels Suppl<\/i> 1992; 7: 133\u2013137. PMID: 1360959","DOI":"10.1007\/BF01744559"},{"key":"55","doi-asserted-by":"crossref","unstructured":"54. \u3000Shimizu M, Ueno K, Ishikawa S, et al. Successful multitarget therapy using mizoribine and tacrolimus for refractory Takayasu arteritis. <i>Rheumatology (Oxford)<\/i> 2014; 53: 1530\u20131532. PMID: 24609060","DOI":"10.1093\/rheumatology\/keu028"},{"key":"56","doi-asserted-by":"crossref","unstructured":"55. \u3000Goel R, Danda D, Mathew J, et al. Mycophenolate mofetil in Takayasu\u2019s arteritis. <i>Clin Rheumatol<\/i> 2010; 29: 329\u2013332. PMID: 20054700","DOI":"10.1007\/s10067-009-1333-6"},{"key":"57","unstructured":"56. \u3000Guideline for Management of Vasculitis Syndrome (JCS 2008). <i>Circ J<\/i> 2008; 72 Suppl IV: 1260\u20131275. http:\/\/www.j-circ.or.jp\/guideline\/pdf\/JCS2008_ozaki_h.pdf"},{"key":"58","unstructured":"57. \u3000Valsakumar AK, Valappil UC, Jorapur V, et al. Role of immunosuppressive therapy on clinical, immunological, and angiographic outcome in active Takayasu\u2019s arteritis. <i>J Rheumatol<\/i> 2003; 30: 1793\u20131798. PMID: 12913937"},{"key":"59","doi-asserted-by":"crossref","unstructured":"58. \u3000Hoffman GS, Leavitt RY, Kerr GS, et al. Treatment of glucocorticoidresistant or relapsing Takayasu arteritis with methotrexate. <i>Arthritis Rheum<\/i> 1994; 37: 578\u2013582. PMID: 7908520","DOI":"10.1002\/art.1780370420"},{"key":"60","doi-asserted-by":"crossref","unstructured":"59. \u3000Ohigashi H, Tamura N, Ebana Y, et al. Effects of immunosuppressive and biological agents on refractory Takayasu arteritis patients unresponsive to glucocorticoid treatment. <i>J Cardiol<\/i> 2017; 69: 774\u2013778. PMID: 27567177","DOI":"10.1016\/j.jjcc.2016.07.009"},{"key":"61","doi-asserted-by":"crossref","unstructured":"60. \u3000Shinjo SK, Pereira RM, Tizziani VA, et al. Mycophenolate mofetil reduces disease activity and steroid dosage in Takayasu arteritis. <i>Clin Rheumatol<\/i> 2007; 26: 1871\u20131875. PMID: 17332971","DOI":"10.1007\/s10067-007-0596-z"},{"key":"62","doi-asserted-by":"crossref","unstructured":"61. \u3000Yokoe I, Haraoka H, Harashima H. A patient with Takayasu\u2019s arteritis and rheumatoid arthritis who responded to tacrolimus hydrate. <i>Intern Med<\/i> 2007; 46: 1873\u20131877. PMID: 18025771","DOI":"10.2169\/internalmedicine.46.0211"},{"key":"63","doi-asserted-by":"crossref","unstructured":"62. \u3000Yamazaki H, Nanki T, Harigai M, et al. Successful treatment of refractory Takayasu arteritis with tacrolimus. <i>J Rheumatol<\/i> 2012; 39: 1487\u20131488. PMID: 22753804","DOI":"10.3899\/jrheum.120078"},{"key":"64","doi-asserted-by":"crossref","unstructured":"63. \u3000Kusunoki R, Ishihara S, Sato M, et al. Rare case of Takayasu\u2019s arteritis associated with Crohn\u2019s disease. <i>Intern Med<\/i> 2011; 50: 1581\u20131585. PMID: 21804285","DOI":"10.2169\/internalmedicine.50.5406"},{"key":"65","doi-asserted-by":"crossref","unstructured":"64. \u3000Horigome H, Kamoda T, Matsui A. Treatment of glucocorticoiddependent Takayasu\u2019s arteritis with cyclosporin. <i>Med J Aust<\/i> 1999; 170: 566. PMID: 10397054","DOI":"10.5694\/j.1326-5377.1999.tb127892.x"},{"key":"66","doi-asserted-by":"crossref","unstructured":"65. \u3000Nishimoto N, Nakahara H, Yoshio-Hoshino N, et al. Successful treatment of a patient with Takayasu arteritis using a humanized antiinterleukin-6 receptor antibody. <i>Arthritis Rheum<\/i> 2008; 58: 1197\u20131200. PMID: 18383395","DOI":"10.1002\/art.23373"},{"key":"67","doi-asserted-by":"crossref","unstructured":"66. \u3000Abisror N, Mekinian A, Lavigne C, et al. Club Rhumatismes et Inflammation, and SNFMI. Tocilizumab in refractory Takayasu arteritis: A case series and updated literature review. <i>Autoimmun Rev<\/i> 2013; 12: 1143\u20131149. PMID: 23820042","DOI":"10.1016\/j.autrev.2013.06.019"},{"key":"68","doi-asserted-by":"crossref","unstructured":"67. \u3000Salvarani C, Magnani L, Catanoso M, et al. Tocilizumab: A novel therapy for patients with large-vessel vasculitis. <i>Rheumatology (Oxford)<\/i> 2012; 51: 151\u2013156. PMID: 22075063","DOI":"10.1093\/rheumatology\/ker296"},{"key":"69","doi-asserted-by":"crossref","unstructured":"68. \u3000Seitz M, Reichenbach S, Bonel HM, et al. Rapid induction of remission in large vessel vasculitis by IL-6 blockade: A case series. <i>Swiss Med Wkly<\/i> 2011; 141: w13156. PMID: 21243547","DOI":"10.4414\/smw.2011.13156"},{"key":"70","doi-asserted-by":"crossref","unstructured":"69. \u3000Unizony S, Arias-Urdaneta L, Miloslavsky E, et al. Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica. <i>Arthritis Care Res (Hoboken)<\/i> 2012; 64: 1720\u20131729. PMID: 22674883","DOI":"10.1002\/acr.21750"},{"key":"71","doi-asserted-by":"crossref","unstructured":"70. \u3000Nakaoka Y, Higuchi K, Arita Y, et al. Tocilizumab for the treatment of patients with refractory Takayasu arteritis. <i>Int Heart J<\/i> 2013; 54: 405\u2013411. PMID: 24309452","DOI":"10.1536\/ihj.54.405"},{"key":"72","doi-asserted-by":"crossref","unstructured":"71. \u3000Mekinian A, Comarmond C, Resche-Rigon M, et al. French Takayasu Network. Efficacy of biological-targeted treatments in Takayasu arteritis: Multicenter, retrospective study of 49 patients. <i>Circulation<\/i> 2015; 132: 1693\u20131700. PMID: 26354797","DOI":"10.1161\/CIRCULATIONAHA.114.014321"},{"key":"73","doi-asserted-by":"crossref","unstructured":"72. \u3000Nakaoka Y, Isobe M, Takei S, et al. Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: Results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study). <i>Ann Rheum Dis<\/i> 2018; 77: 348\u2013354. PMID: 29191819","DOI":"10.1136\/annrheumdis-2017-211878"},{"key":"74","doi-asserted-by":"crossref","unstructured":"73. \u3000Hoffman GS, Merkel PA, Brasington RD, et al. Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. <i>Arthritis Rheum<\/i> 2004; 50: 2296\u20132304. PMID: 15248230","DOI":"10.1002\/art.20300"},{"key":"75","doi-asserted-by":"crossref","unstructured":"74. \u3000Schmidt J, Kermani TA, Bacani AK, et al. Tumor necrosis factor inhibitors in patients with Takayasu arteritis: Experience from a referral center with long-term followup. <i>Arthritis Care Res (Hoboken)<\/i> 2012; 64: 1079\u20131083. PMID: 22328491","DOI":"10.1002\/acr.21636"},{"key":"76","doi-asserted-by":"crossref","unstructured":"75. \u3000de Souza AW, Machado NP, Pereira VM, et al. Antiplatelet therapy for the prevention of arterial ischemic events in takayasu arteritis. <i>Circ J<\/i> 2010; 74: 1236\u20131241. PMID: 20467149","DOI":"10.1253\/circj.CJ-09-0905"},{"key":"77","doi-asserted-by":"crossref","unstructured":"76. \u3000Fields CE, Bower TC, Cooper LT, et al. Takayasu\u2019s arteritis: Operative results and influence of disease activity. <i>J Vasc Surg<\/i> 2006; 43: 64\u201371. PMID: 16414389","DOI":"10.1016\/j.jvs.2005.10.010"},{"key":"78","doi-asserted-by":"crossref","unstructured":"77. \u3000Min PK, Park S, Jung JH, et al. Endovascular therapy combined with immunosuppressive treatment for occlusive arterial disease in patients with Takayasu\u2019s arteritis. <i>J Endovasc Ther<\/i> 2005; 12: 28\u201334. PMID: 15683269","DOI":"10.1583\/12-01-04-1329.1"},{"key":"79","doi-asserted-by":"crossref","unstructured":"78. \u3000Park MC, Lee SW, Park YB, et al. Post-interventional immunosuppressive treatment and vascular restenosis in Takayasu\u2019s arteritis. <i>Rheumatology (Oxford)<\/i> 2006; 45: 600\u2013605. PMID: 16352637","DOI":"10.1093\/rheumatology\/kei245"},{"key":"80","doi-asserted-by":"crossref","unstructured":"79. \u3000Perera AH, Youngstein T, Gibbs RG, et al. Optimizing the outcome of vascular intervention for Takayasu arteritis. <i>Br J Surg<\/i> 2014; 101: 43\u201350. PMID: 24375298","DOI":"10.1002\/bjs.9372"},{"key":"81","doi-asserted-by":"crossref","unstructured":"80. \u3000Saadoun D, Lambert M, Mirault T, et al. Retrospective analysis of surgery versus endovascular intervention in Takayasu arteritis: A multicenter experience. <i>Circulation<\/i> 2012; 125: 813\u2013819. PMID: 22230484","DOI":"10.1161\/CIRCULATIONAHA.111.058032"},{"key":"82","doi-asserted-by":"crossref","unstructured":"81. \u3000Ueno A, Awane Y, Wakabayashi A, et al. Successfully operated obliterative brachiocephalic arteritis (Takayasu) associated with the elongated coarctation. <i>Jpn Heart J<\/i> 1967; 8: 538\u2013544. PMID: 5299711","DOI":"10.1536\/ihj.8.538"},{"key":"83","doi-asserted-by":"crossref","unstructured":"82. \u3000Uyama M, Asayama K. Retinal Vascular Changes in Takayasu\u2019s Disease (Pulseless Disease), Occurrence and Evolution of the Lesion.<i>In<\/i>: Doc Ophthalmol Proc Ser 9. 1976: 549\u2013554.","DOI":"10.1007\/978-94-010-1573-8_78"},{"key":"84","doi-asserted-by":"crossref","unstructured":"83. \u3000Tada Y, Sato O, Ohshima A, et al. Surgical treatment of Takayasu arteritis. <i>Heart Vessels Suppl<\/i> 1992; 7: 159\u2013167. PMID: 1360963","DOI":"10.1007\/BF01744563"},{"key":"85","doi-asserted-by":"crossref","unstructured":"84. \u3000Pajari R, Hekali P, Harjola PT. Treatment of Takayasu\u2019s arteritis: An analysis of 29 operated patients. <i>Thorac Cardiovasc Surg<\/i> 1986; 34: 176\u2013181. PMID: 2426832","DOI":"10.1055\/s-2007-1020404"},{"key":"86","unstructured":"85. \u3000Wu X, Duan HY, Gu YQ, et al. Surgical treatment of brachiocephalic vessel involvement in Takayasu\u2019s arteritis. <i>Chin Med J (Engl)<\/i> 2010; 123: 1122\u20131126. PMID: 20529549"},{"key":"87","doi-asserted-by":"crossref","unstructured":"86. \u3000Kumar A, Dubey D, Bansal P, et al. Surgical and radiological management of renovascular hypertension in a developing country. <i>J Urol<\/i> 2003; 170: 727\u2013730. PMID: 12913683","DOI":"10.1097\/01.ju.0000081997.69890.f3"},{"key":"88","doi-asserted-by":"crossref","unstructured":"87. \u3000Miyata T, Sato O, Koyama H, et al. Long-term survival after surgical treatment of patients with Takayasu\u2019s arteritis. <i>Circulation<\/i> 2003; 108: 1474\u20131480. PMID: 12952846","DOI":"10.1161\/01.CIR.0000089089.42153.5E"},{"key":"89","doi-asserted-by":"crossref","unstructured":"88. \u3000Kim YW, Kim DI, Park YJ, et al. Surgical bypass vs endovascular treatment for patients with supra-aortic arterial occlusive disease due to Takayasu arteritis. <i>J Vasc Surg<\/i> 2012; 55: 693\u2013700. PMID: 22119246","DOI":"10.1016\/j.jvs.2011.09.051"},{"key":"90","doi-asserted-by":"crossref","unstructured":"89. \u3000Mason JC. Takayasu arteritis: Surgical interventions. <i>Curr Opin Rheumatol<\/i> 2015; 27: 45\u201352. PMID: 25405823","DOI":"10.1097\/BOR.0000000000000127"},{"key":"91","doi-asserted-by":"crossref","unstructured":"90. \u3000Lee GY, Jeon P, Do YS, et al. Comparison of outcomes between endovascular treatment and bypass surgery in Takayasu arteritis. <i>Scand J Rheumatol<\/i> 2014; 43: 153\u2013161. PMID: 24134435","DOI":"10.3109\/03009742.2013.822096"},{"key":"92","unstructured":"91. \u3000Vahanian A, Alfieri O, Andreotti F, et al. Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC): Guidelines on the management of valvular heart disease (version 2012). <i>Eur Heart J<\/i> 2012; 33: 2451\u20132496. PMID: 22922415"},{"key":"93","unstructured":"92. \u3000Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA\/ACC guideline for the management of patients with valvular heart disease: A report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. <i>J Thorac Cardiovasc Surg<\/i> 2014; 148: e1\u2013e132. PMID: 24939033"},{"key":"94","unstructured":"93. \u3000Enomoto S, Miyamoto T, Shimada I, et al. Surgical therapy for aortic regurgitation due to aortitis syndrome: Effectiveness and extended indication of Bentall\u2019s operation. <i>Jpn J Thorac and Cardiovasc Surg<\/i> 1992; 40: 500\u2013505."},{"key":"95","doi-asserted-by":"crossref","unstructured":"94. \u3000Ando M, Kosakai Y, Okita Y, et al. Surgical treatment for aortic regurgitation caused by Takayasu\u2019s arteritis. <i>J Card Surg<\/i> 1998; 13: 202\u2013207. PMID: 10193991","DOI":"10.1111\/j.1540-8191.1998.tb01263.x"},{"key":"96","doi-asserted-by":"crossref","unstructured":"95. \u3000Ando M, Okita Y, Sasako Y, et al. Evaluation of the results of surgical treatment for dilative lesions associated with Takayasu\u2019s arteritis. <i>Int J Angiol<\/i> 2000; 9: 194\u2013197.","DOI":"10.1007\/BF01616506"},{"key":"97","doi-asserted-by":"crossref","unstructured":"96. \u3000Ogino H, Matsuda H, Minatoya K, et al. Overview of late outcome of medical and surgical treatment for Takayasu arteritis. <i>Circulation<\/i> 2008; 118: 2738\u20132747. PMID: 19106398","DOI":"10.1161\/CIRCULATIONAHA.107.759589"},{"key":"98","doi-asserted-by":"crossref","unstructured":"97. \u3000Matsuura K, Ogino H, Kobayashi J, et al. Surgical treatment of aortic regurgitation due to Takayasu arteritis: Long-term morbidity and mortality. <i>Circulation<\/i> 2005; 112: 3707\u20133712. PMID: 16330687","DOI":"10.1161\/CIRCULATIONAHA.105.535724"},{"key":"99","doi-asserted-by":"crossref","unstructured":"98. \u3000Fujiwara T, Masaki H, Yamane H, et al. Coronary ostial endarterectomy in Takayasu\u2019s aortitis: Confirmation of patency nine years postsurgically. <i>Jpn Circ J<\/i> 1992; 56: 556\u2013559. PMID: 1352558","DOI":"10.1253\/jcj.56.556"},{"key":"100","doi-asserted-by":"crossref","unstructured":"99. \u3000Dong H, Jiang X, Peng M, et al. Percutaneous transluminal angioplasty for symptomatic pulmonary stenosis in Takayasu arteritis. <i>J Rheumatol<\/i> 2014; 41: 1856\u20131862. PMID: 25128508","DOI":"10.3899\/jrheum.131007"},{"key":"101","doi-asserted-by":"crossref","unstructured":"100. \u3000Ishikawa K, Maetani S. Long-term outcome for 120 Japanese patients with Takayasu\u2019s disease: Clinical and statistical analyses of related prognostic factors. <i>Circulation<\/i> 1994; 90: 1855\u20131860. PMID: 7923672","DOI":"10.1161\/01.CIR.90.4.1855"},{"key":"102","doi-asserted-by":"crossref","unstructured":"101. \u3000Schmidt J, Kermani TA, Bacani AK, et al. Diagnostic features, treatment, and outcomes of Takayasu arteritis in a US cohort of 126 patients. <i>Mayo Clin Proc<\/i> 2013; 88: 822\u2013830. PMID: 23849994","DOI":"10.1016\/j.mayocp.2013.04.025"},{"key":"103","doi-asserted-by":"crossref","unstructured":"102. \u3000Maeda M, Kobayashi M, Okamoto S, et al. Aortitis syndrome in children: Clinical observation of 35 cases in Japan. <i>Acta Paediatr Jpn<\/i> 1997; 39: 280\u2013284. PMID: 9141273","DOI":"10.1111\/j.1442-200X.1997.tb03600.x"},{"key":"104","unstructured":"103. \u3000Nakano N. Study of intractable pathology and treatment of vasculitis syndrome in children (Takayasu arteritis). Health and Labour Sciences Research Grant (Research Project for the Prevention and Treatment of Immunological and Allergic Diseases) Study of the Diagnosis and Treatment of Intractable Pathology of Rheumatism\/Collagen Disease in Childhood. Report in 2010."},{"key":"105","unstructured":"104. \u3000Information Center for Chronic Diseases, Japan. https:\/\/www.shouman.jp\/"},{"key":"106","doi-asserted-by":"crossref","unstructured":"105. \u3000Batu ED, S\u00f6nmez HE, Haz\u0131rolan T, et al. Tocilizumab treatment in childhood Takayasu arteritis: Case series of four patients and systematic review of the literature. <i>Semin Arthritis Rheum<\/i> 2017; 46: 529\u2013535. PMID: 27515155","DOI":"10.1016\/j.semarthrit.2016.07.012"},{"key":"107","doi-asserted-by":"crossref","unstructured":"106. \u3000Kobayashi S, Yano T, Matsumoto Y, et al. Clinical and epidemiologic analysis of giant cell (temporal) arteritis from a nationwide survey in 1998 in Japan: The first government-supported nationwide survey. <i>Arthritis Rheum<\/i> 2003; 49: 594\u2013598. PMID: 12910568","DOI":"10.1002\/art.11195"},{"key":"108","doi-asserted-by":"crossref","unstructured":"107. \u3000Carmona FD, Gonz\u00e1lez-Gay MA, Mart\u00edn J. Genetic component of giant cell arteritis. <i>Rheumatology (Oxford)<\/i> 2014; 53: 6\u201318. PMID: 23843109","DOI":"10.1093\/rheumatology\/ket231"},{"key":"109","unstructured":"108. \u3000Carmona FD, Mackie SL, Mart\u00edn JE, et al. Spanish GCA Group. A large-scale genetic analysis reveals a strong contribution of the HLA class II region to giant cell arteritis susceptibility. <i>Am J Hum Genet<\/i> 2015; 96: 565\u2013580. PMID: 25817017"},{"key":"110","unstructured":"109. \u3000Elling P, Olsson AT, Elling H. Synchronous variations of the incidence of temporal arteritis and polymyalgia rheumatica in different regions of Denmark; association with epidemics of Mycoplasma pneumoniae infection. <i>J Rheumatol<\/i> 1996; 23: 112\u2013119. PMID: 8838518"},{"key":"111","unstructured":"110. \u3000Health and Labour Sciences Research Grant \u2013 Policy Research Project on Intractable Diseases Study Group on Intractable Vasculitis. Vasculitis Pathology Atlas, web edition. http:\/\/www.vas-mhlw.org\/html\/pathology\/index.html"},{"key":"112","doi-asserted-by":"crossref","unstructured":"111. \u3000Singh AG, Kermani TA, Crowson CS, et al. Visual manifestations in giant cell arteritis: Trend over 5 decades in a population-based cohort. <i>J Rheumatol<\/i> 2015; 42: 309\u2013315. PMID: 25512481","DOI":"10.3899\/jrheum.140188"},{"key":"113","doi-asserted-by":"crossref","unstructured":"112. \u3000Muratore F, Kermani TA, Crowson CS, et al. Large-vessel giant cell arteritis: A cohort study. <i>Rheumatology (Oxford)<\/i> 2015; 54: 463\u2013470. PMID: 25193809","DOI":"10.1093\/rheumatology\/keu329"},{"key":"114","doi-asserted-by":"crossref","unstructured":"113. \u3000Salvarani C, Cantini F, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. <i>Lancet<\/i> 2008; 372: 234\u2013245. PMID: 18640460","DOI":"10.1016\/S0140-6736(08)61077-6"},{"key":"115","doi-asserted-by":"crossref","unstructured":"114. \u3000Mazlumzadeh M, Hunder GG, Easley KA, et al. Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: A double-blind, placebo-controlled, randomized prospective clinical trial. <i>Arthritis Rheum<\/i> 2006; 54: 3310\u20133318. PMID: 17009270","DOI":"10.1002\/art.22163"},{"key":"116","doi-asserted-by":"crossref","unstructured":"115. \u3000Seror R, Baron G, Hachulla E, et al. Adalimumab for steroid sparing in patients with giant-cell arteritis: Results of a multicentre randomized controlled trial. <i>Ann Rheum Dis<\/i> 2014; 73: 2074\u20132081. PMID: 23897775","DOI":"10.1136\/annrheumdis-2013-203586"},{"key":"117","doi-asserted-by":"crossref","unstructured":"116. \u3000Mahr AD, Jover JA, Spiera RF, et al. Adjunctive methotrexate for treatment of giant cell arteritis: An individual patient data meta-analysis. <i>Arthritis Rheum<\/i> 2007; 56: 2789\u20132797. PMID: 17665429","DOI":"10.1002\/art.22754"},{"key":"118","doi-asserted-by":"crossref","unstructured":"117. \u3000Weyand CM, Fulbright JW, Hunder GG, et al. Treatment of giant cell arteritis: Interleukin-6 as a biologic marker of disease activity. <i>Arthritis Rheum<\/i> 2000; 43: 1041\u20131048. PMID: 10817557","DOI":"10.1002\/1529-0131(200005)43:5<1041::AID-ANR12>3.0.CO;2-7"},{"key":"119","doi-asserted-by":"crossref","unstructured":"118. \u3000Roche NE, Fulbright JW, Wagner AD, et al. Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritis. <i>Arthritis Rheum<\/i> 1993; 36: 1286\u20131294. PMID: 8216422","DOI":"10.1002\/art.1780360913"},{"key":"120","doi-asserted-by":"crossref","unstructured":"119. \u3000Blockmans D. Diagnosis and extension of giant cell arteritis. Contribution of imaging techniques. <i>Presse Med<\/i> 2012; 41: 948\u2013954. PMID: 22795837","DOI":"10.1016\/j.lpm.2012.05.014"},{"key":"121","doi-asserted-by":"crossref","unstructured":"120. \u3000Schmidt WA, Kraft HE, Vorpahl K, et al. Color duplex ultrasonography in the diagnosis of temporal arteritis. <i>N Engl J Med<\/i> 1997; 337: 1336\u20131342. PMID: 9358127","DOI":"10.1056\/NEJM199711063371902"},{"key":"122","doi-asserted-by":"crossref","unstructured":"121. \u3000Salvarani C, Silingardi M, Ghirarduzzi A, et al. Is duplex ultrasonography useful for the diagnosis of giant-cell arteritis? <i>Ann Intern Med<\/i> 2002; 137: 232\u2013238. PMID: 12186513","DOI":"10.7326\/0003-4819-137-4-200208200-00006"},{"key":"123","doi-asserted-by":"crossref","unstructured":"122. \u3000Nordborg E, Nordborg C. Giant cell arteritis: Strategies in diagnosis and treatment. <i>Curr Opin Rheumatol<\/i> 2004; 16: 25\u201330. PMID: 14673385","DOI":"10.1097\/00002281-200401000-00006"},{"key":"124","doi-asserted-by":"crossref","unstructured":"123. \u3000Liu GT, Glaser JS, Schatz NJ, et al. Visual morbidity in giant cell arteritis: Clinical characteristics and prognosis for vision. <i>Ophthalmology<\/i> 1994; 101: 1779\u20131785. PMID: 7800356","DOI":"10.1016\/S0161-6420(94)31102-X"},{"key":"125","unstructured":"124. \u3000Liozon E, Boutros-Toni F, Ly K, et al. Silent, or masked, giant cell arteritis is associated with a strong inflammatory response and a benign short term course. <i>J Rheumatol<\/i> 2003; 30: 1272\u20131276. PMID: 12784402"},{"key":"126","doi-asserted-by":"crossref","unstructured":"125. \u3000Hayreh SS, Podhajsky PA, Zimmerman B. Ocular manifestations of giant cell arteritis. <i>Am J Ophthalmol<\/i> 1998; 125: 509\u2013520. PMID: 9559737","DOI":"10.1016\/S0002-9394(99)80192-5"},{"key":"127","unstructured":"126. \u3000Tanano I, Kinouchi R, Ohya S, et al. Gradual visual loss after visual recovery by pulsed corticosteroid therapy in a patient with biopsy-proven giant cell arteritis. <i>Ophthalmol<\/i> 2011; 53: 1769\u20131773."},{"key":"128","doi-asserted-by":"crossref","unstructured":"127. \u3000Hamidou MA, Batard E, Trewick D, et al. Silent versus cranial giant cell arteritis. Initial presentation and outcome of 50 biopsy-proven cases. <i>Eur J Intern Med<\/i> 2005; 16: 183\u2013186. PMID: 15967333","DOI":"10.1016\/j.ejim.2005.02.001"},{"key":"129","doi-asserted-by":"crossref","unstructured":"128. \u3000Cid MC, Font C, Oristrell J, et al. Association between strong inflammatory response and low risk of developing visual loss and other cranial ischemic complications in giant cell (temporal) arteritis. <i>Arthritis Rheum<\/i> 1998; 41: 26\u201332. PMID: 9433866","DOI":"10.1002\/1529-0131(199801)41:1<26::AID-ART4>3.0.CO;2-0"},{"key":"130","doi-asserted-by":"crossref","unstructured":"129. \u3000Hunder GG, Bloch DA, Michel BA, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. <i>Arthritis Rheum<\/i> 1990; 33: 1122\u20131128. PMID: 2202311","DOI":"10.1002\/art.1780330810"},{"key":"131","doi-asserted-by":"crossref","unstructured":"130. \u3000Karassa FB, Matsagas MI, Schmidt WA, et al. Meta-analysis: Test performance of ultrasonography for giant-cell arteritis. <i>Ann Intern Med<\/i> 2005; 142: 359\u2013369. PMID: 15738455","DOI":"10.7326\/0003-4819-142-5-200503010-00011"},{"key":"132","unstructured":"131. \u3000Nesher G, Shemesh D, Mates M, et al. The predictive value of the halo sign in color Doppler ultrasonography of the temporal arteries for diagnosing giant cell arteritis. <i>J Rheumatol<\/i> 2002; 29: 1224\u20131226. PMID: 12064840"},{"key":"133","doi-asserted-by":"crossref","unstructured":"132. \u3000Smetana GW, Shmerling RH. Does this patient have temporal arteritis? <i>JAMA<\/i> 2002; 287: 92\u2013101. PMID: 11754714","DOI":"10.1001\/jama.287.1.92"},{"key":"134","doi-asserted-by":"crossref","unstructured":"133. \u3000Muratore F, Cavazza A, Boiardi L, et al. Histopathologic findings of patients with biopsy-negative giant cell arteritis compared to those without arteritis: A population-based study. <i>Arthritis Care Res (Hoboken)<\/i> 2016; 68: 865\u2013870. PMID: 26415044","DOI":"10.1002\/acr.22736"},{"key":"135","unstructured":"134. \u3000Breuer GS, Nesher R, Nesher G. Negative temporal artery biopsies: Eventual diagnoses and features of patients with biopsy-negative giant cell arteritis compared to patients without arteritis. <i>Clin Exp Rheumatol<\/i> 2008; 26: 1103\u20131106. PMID: 19210879"},{"key":"136","doi-asserted-by":"crossref","unstructured":"135. \u3000Esteban MJ, Font C, Hern\u00e1ndez-Rodr\u00edguez J, et al. Small-vessel vasculitis surrounding a spared temporal artery: Clinical and pathological findings in a series of twenty-eight patients. <i>Arthritis Rheum<\/i> 2001; 44: 1387\u20131395. PMID: 11407699","DOI":"10.1002\/1529-0131(200106)44:6<1387::AID-ART232>3.0.CO;2-B"},{"key":"137","doi-asserted-by":"crossref","unstructured":"136. \u3000G\u00e9n\u00e9reau T, Lortholary O, Pottier MA, et al. French Vasculitis Study Group. Temporal artery biopsy: A diagnostic tool for systemic necrotizing vasculitis. <i>Arthritis Rheum<\/i> 1999; 42: 2674\u20132681. PMID: 10616017","DOI":"10.1002\/1529-0131(199912)42:12<2674::AID-ANR25>3.0.CO;2-A"},{"key":"138","doi-asserted-by":"crossref","unstructured":"137. \u3000Salvarani C, Gabriel SE, Gertz MA, et al. Primary systemic amyloidosis presenting as giant cell arteritis and polymyalgia rheumatica. <i>Arthritis Rheum<\/i> 1994; 37: 1621\u20131626. PMID: 7980674","DOI":"10.1002\/art.1780371111"},{"key":"139","doi-asserted-by":"crossref","unstructured":"138. \u3000Salvarani C, Hunder GG. Giant cell arteritis with low erythrocyte sedimentation rate: Frequency of occurence in a population-based study. <i>Arthritis Rheum<\/i> 2001; 45: 140\u2013145. PMID: 11324777","DOI":"10.1002\/1529-0131(200104)45:2<140::AID-ANR166>3.0.CO;2-2"},{"key":"140","unstructured":"139. \u3000Salvarani C, Cantini F, Boiardi L, et al. Laboratory investigations useful in giant cell arteritis and Takayasu\u2019s arteritis. <i>Clin Exp Rheumatol<\/i> 2003; 21 Suppl: S23\u2013S28. PMID: 14740424"},{"key":"141","doi-asserted-by":"crossref","unstructured":"140. \u3000Mukhtyar C, Guillevin L, Cid MC, et al. European Vasculitis Study Group. EULAR recommendations for the management of large vessel vasculitis. <i>Ann Rheum Dis<\/i> 2009; 68: 318\u2013323. PMID: 18413441","DOI":"10.1136\/ard.2008.088351"},{"key":"142","doi-asserted-by":"crossref","unstructured":"141. \u3000Achkar AA, Lie JT, Hunder GG, et al. How does previous corticosteroid treatment affect the biopsy findings in giant cell (temporal) arteritis? <i>Ann Intern Med<\/i> 1994; 120: 987\u2013992. PMID: 8185147","DOI":"10.7326\/0003-4819-120-12-199406150-00003"},{"key":"143","doi-asserted-by":"crossref","unstructured":"142. \u3000Brack A, Martinez-Taboada V, Stanson A, et al. Disease pattern in cranial and large-vessel giant cell arteritis. <i>Arthritis Rheum<\/i> 1999; 42: 311\u2013317. PMID: 10025926","DOI":"10.1002\/1529-0131(199902)42:2<311::AID-ANR14>3.0.CO;2-F"},{"key":"144","doi-asserted-by":"crossref","unstructured":"143. \u3000Kermani TA, Warrington KJ, Crowson CS, et al. Large-vessel involvement in giant cell arteritis: A population-based cohort study of the incidence-trends and prognosis. <i>Ann Rheum Dis<\/i> 2013; 72: 1989\u20131994. PMID: 23253927","DOI":"10.1136\/annrheumdis-2012-202408"},{"key":"145","doi-asserted-by":"crossref","unstructured":"144. \u3000Nuenninghoff DM, Hunder GG, Christianson TJ, et al. Incidence and predictors of large-artery complication (aortic aneurysm, aortic dissection, and\/or large-artery stenosis) in patients with giant cell arteritis: A population-based study over 50 years. <i>Arthritis Rheum<\/i> 2003; 48: 3522\u20133531. PMID: 14674004","DOI":"10.1002\/art.11353"},{"key":"146","doi-asserted-by":"crossref","unstructured":"145. \u3000Robson JC, Kiran A, Maskell J, et al. The relative risk of aortic aneurysm in patients with giant cell arteritis compared with the general population of the UK. <i>Ann Rheum Dis<\/i> 2015; 74: 129\u2013135. PMID: 24095936","DOI":"10.1136\/annrheumdis-2013-204113"},{"key":"147","doi-asserted-by":"crossref","unstructured":"146. \u3000Nuenninghoff DM, Hunder GG, Christianson TJ, et al. Mortality of large-artery complication (aortic aneurysm, aortic dissection, and\/or large-artery stenosis) in patients with giant cell arteritis: A population-based study over 50 years. <i>Arthritis Rheum<\/i> 2003; 48: 3532\u20133537. PMID: 14674005","DOI":"10.1002\/art.11480"},{"key":"148","doi-asserted-by":"crossref","unstructured":"147. \u3000Andersson R, Malmvall BE, Bengtsson BA. Long-term corticosteroid treatment in giant cell arteritis. <i>Acta Med Scand<\/i> 1986; 220: 465\u2013469. PMID: 3812030","DOI":"10.1111\/j.0954-6820.1986.tb02796.x"},{"key":"149","doi-asserted-by":"crossref","unstructured":"148. \u3000Proven A, Gabriel SE, Orces C, et al. Glucocorticoid therapy in giant cell arteritis: Duration and adverse outcomes. <i>Arthritis Rheum<\/i> 2003; 49: 703\u2013708. PMID: 14558057","DOI":"10.1002\/art.11388"},{"key":"150","doi-asserted-by":"crossref","unstructured":"149. \u3000Yates M, Loke YK, Watts RA, et al. Prednisolone combined with adjunctive immunosuppression is not superior to prednisolone alone in terms of efficacy and safety in giant cell arteritis: Meta-analysis. <i>Clin Rheumatol<\/i> 2014; 33: 227\u2013236. PMID: 24026674","DOI":"10.1007\/s10067-013-2384-2"},{"key":"151","unstructured":"150. \u3000Henes JC, Mueller M, Pfannenberg C, et al. Cyclophosphamide for large vessel vasculitis: Assessment of response by PET\/CT. <i>Clin Exp Rheumatol<\/i> 2011; 29 Suppl: S43\u2013S48. PMID: 21385544"},{"key":"152","unstructured":"151. \u3000Loock J, Henes J, K\u00f6tter I, et al. Treatment of refractory giant cell arteritis with cyclophosphamide: A retrospective analysis of 35 patients from three centres. <i>Clin Exp Rheumatol<\/i> 2012; 30 Suppl: S70\u2013S76. PMID: 22640650"},{"key":"153","doi-asserted-by":"crossref","unstructured":"152. \u3000de Boysson H, Boutemy J, Creveuil C, et al. Is there a place for cyclophosphamide in the treatment of giant-cell arteritis? A case series and systematic review. <i>Semin Arthritis Rheum<\/i> 2013; 43: 105\u2013112. PMID: 23453684","DOI":"10.1016\/j.semarthrit.2012.12.023"},{"key":"154","doi-asserted-by":"crossref","unstructured":"153. \u3000Quartuccio L, Maset M, De Maglio G, et al. Role of oral cyclophosphamide in the treatment of giant cell arteritis. <i>Rheumatology (Oxford)<\/i> 2012; 51: 1677\u20131686. PMID: 22627726","DOI":"10.1093\/rheumatology\/kes127"},{"key":"155","doi-asserted-by":"crossref","unstructured":"154. \u3000De Silva M, Hazleman BL. Azathioprine in giant cell arteritis\/polymyalgia rheumatica: A double-blind study. <i>Ann Rheum Dis<\/i> 1986; 45: 136\u2013138. PMID: 3511861","DOI":"10.1136\/ard.45.2.136"},{"key":"156","doi-asserted-by":"crossref","unstructured":"155. \u3000Boureau AS, de Faucal P, Espitia O, et al. Place of azathioprine in the treatment of giant cell arteritis. [Article in French] <i>Rev Med Interne<\/i> 2016; 37: 723\u2013729. PMID: 27260788","DOI":"10.1016\/j.revmed.2016.03.007"},{"key":"157","doi-asserted-by":"crossref","unstructured":"156. \u3000Hoffman GS, Cid MC, Rendt-Zagar KE, et al. Infliximab-GCA Study Group. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: A randomized trial. <i>Ann Intern Med<\/i> 2007; 146: 621\u2013630. PMID: 17470830","DOI":"10.7326\/0003-4819-146-9-200705010-00004"},{"key":"158","doi-asserted-by":"crossref","unstructured":"157. \u3000Villiger PM, Adler S, Kuchen S, et al. Tocilizumab for induction and maintenance of remission in giant cell arteritis: A phase 2, randomised, double-blind, placebo-controlled trial. <i>Lancet<\/i> 2016; 387: 1921\u20131927. PMID: 26952547","DOI":"10.1016\/S0140-6736(16)00560-2"},{"key":"159","doi-asserted-by":"crossref","unstructured":"158. \u3000Unizony SH, Dasgupta B, Fisheleva E, et al. Design of the tocilizumab in giant cell arteritis trial. <i>Int J Rheumatol<\/i> 2013; 2013: 912562. PMID: 23653652","DOI":"10.1155\/2013\/912562"},{"key":"160","unstructured":"159. \u3000Pazzola G, Padovano I, Boiardi L, et al. Tocilizumab in glucocorticoid-na\u00efve large-vessel vasculitis. <i>Clin Exp Rheumatol<\/i> 2013; 31 Suppl: S59\u2013S61. PMID: 23306184"},{"key":"161","doi-asserted-by":"crossref","unstructured":"160. \u3000Loricera J, Blanco R, Hern\u00e1ndez JL, et al. Tocilizumab in giant cell arteritis: Multicenter open-label study of 22 patients. <i>Semin Arthritis Rheum<\/i> 2015; 44: 717\u2013723. PMID: 25697557","DOI":"10.1016\/j.semarthrit.2014.12.005"},{"key":"162","doi-asserted-by":"crossref","unstructured":"161. \u3000Salvarani C, Giannini C, Miller DV, et al. Giant cell arteritis: Involvement of intracranial arteries. <i>Arthritis Rheum<\/i> 2006; 55: 985\u2013989. PMID: 17139651","DOI":"10.1002\/art.22359"},{"key":"163","doi-asserted-by":"crossref","unstructured":"162. \u3000Lee MS, Smith SD, Galor A, et al. Antiplatelet and anticoagulant therapy in patients with giant cell arteritis. <i>Arthritis Rheum<\/i> 2006; 54: 3306\u20133309. PMID: 17009265","DOI":"10.1002\/art.22141"},{"key":"164","doi-asserted-by":"crossref","unstructured":"163. \u3000Nesher G, Berkun Y, Mates M, et al. Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. <i>Arthritis Rheum<\/i> 2004; 50: 1332\u20131337. PMID: 15077317","DOI":"10.1002\/art.20171"},{"key":"165","doi-asserted-by":"crossref","unstructured":"164. \u3000Nesher G, Berkun Y, Mates M, et al. Risk factors for cranial ischemic complications in giant cell arteritis. <i>Medicine (Baltimore)<\/i> 2004; 83: 114\u2013122. PMID: 15028965","DOI":"10.1097\/01.md.0000119761.27564.c9"},{"key":"166","doi-asserted-by":"crossref","unstructured":"165. \u3000Gonzalez-Gay MA, Garcia-Porrua C, Pi\u00f1eiro A, et al. Aortic aneurysm and dissection in patients with biopsy-proven giant cell arteritis from northwestern Spain: A population-based study. <i>Medicine (Baltimore)<\/i> 2004; 83: 335\u2013341. PMID: 15525845","DOI":"10.1097\/01.md.0000145366.40805.f8"},{"key":"167","unstructured":"166. \u3000Dehaine-Bamberger N, Amar R, Touboul C, et al. Buerger disease, clinical and prognostic aspects: 83 cases. [Article in French] <i>Presse Med<\/i> 1993; 22: 945\u2013948. PMID: 8367418"},{"key":"168","doi-asserted-by":"crossref","unstructured":"167. \u3000Mills JL, Taylor LM, Porter JM. Buerger\u2019s disease in the modern era. <i>Am J Surg<\/i> 1987; 154: 123\u2013129. PMID: 3605510","DOI":"10.1016\/0002-9610(87)90301-1"},{"key":"169","doi-asserted-by":"crossref","unstructured":"168. \u3000Lie JT. Thromboangiitis obliterans (Buerger\u2019s disease) in women. <i>Medicine (Baltimore)<\/i> 1987; 66: 65\u201372. PMID: 3492659","DOI":"10.1097\/00005792-198701000-00002"},{"key":"170","unstructured":"169. \u3000Olin JW, Young JR, Graor RA, et al. The changing clinical spectrum of thromboangiitis obliterans (Buerger\u2019s disease). <i>Circulation<\/i> 1990; 82 Suppl: IV3\u2013IV8. PMID: 2225420"},{"key":"171","unstructured":"170. \u3000Shionoya S, Ban I, Nakata Y, et al. Diagnosis, pathology, and treatment of Buerger\u2019s disease. <i>Surgery<\/i> 1974; 75: 695\u2013700. PMID: 4824428"},{"key":"172","doi-asserted-by":"crossref","unstructured":"171. \u3000Adar R, Papa MZ, Halpern Z, et al. Cellular sensitivity to collagen in thromboangiitis obliterans. <i>N Engl J Med<\/i> 1983; 308: 1113\u20131116. PMID: 6835334","DOI":"10.1056\/NEJM198305123081901"},{"key":"173","doi-asserted-by":"crossref","unstructured":"172. \u3000Buerger L. Thromboangiitis obliterans: A study of the vascular lesions leading to presenile spontaneous gangrene. <i>Am J Med Sci<\/i> 1908; 136: 567\u2013580.","DOI":"10.1097\/00000441-190810000-00011"},{"key":"174","doi-asserted-by":"crossref","unstructured":"173. \u3000Gulati SM, Madhra K, Thusoo TK, et al. Autoantibodies in thromboangiitis obliterans (Buerger\u2019s disease). <i>Angiology<\/i> 1982; 33: 642\u2013651. PMID: 6751163","DOI":"10.1177\/000331978203301003"},{"key":"175","unstructured":"174. \u3000Roncon de Albuquerque R, Delgado L, Correia P, et al. Circulating immune complexes in Buerger\u2019s disease. Endarteritis obliterans in young men. <i>J Cardiovasc Surg (Torino)<\/i> 1989; 30: 821\u2013825. PMID: 2808505"},{"key":"176","unstructured":"175. \u3000Majewski W, Marszalek A, Staniszewiski R, et al. Clinical and morphological aspects of Buerger\u2019s disease. <i>Int Angiol<\/i> 1997; 16: 239\u2013244. PMID: 9543220"},{"key":"177","doi-asserted-by":"crossref","unstructured":"176. \u3000Eichhorn J, Sima D, Lindschau C, et al. Antiendothelial cell antibodies in thromboangiitis obliterans. <i>Am J Med Sci<\/i> 1998; 315: 17\u201323. PMID: 9427570","DOI":"10.1097\/00000441-199801000-00004"},{"key":"178","unstructured":"177. \u3000Shionoya S, Leu HJ, Lie JT. Buerger\u2019s disease (thromboangiitis obliterans).<i>In<\/i>: Stehbens WE, Lie JT, editors. Vascular pathology. Chapman &amp; Hall Medical, 1995: 657\u2013678."},{"key":"179","unstructured":"178. \u3000Juergens JL. Thromboangiitis obliterans (Buerger\u2019s disease, TAO).<i>In<\/i>: Juergens JL, Spittel JA, Fairbairn JF, editors. Peripheral vascular diseases. WB Saunders, 1980: 469\u2013491."},{"key":"180","doi-asserted-by":"crossref","unstructured":"179. \u3000Allen EV, Brown GE. Thromboangiitis obliterans. A clinical study of 200 cases. <i>Ann Intern Med<\/i> 1928; 1: 535\u2013549.","DOI":"10.7326\/0003-4819-1-8-535"},{"key":"181","doi-asserted-by":"crossref","unstructured":"180. \u3000Iwai T, Inoue Y, Umeda M, et al. Oral bacteria in the occluded arteries of patients with Buerger disease. <i>J Vasc Surg<\/i> 2005; 42: 107\u2013115. PMID: 16012459","DOI":"10.1016\/j.jvs.2005.03.016"},{"key":"182","doi-asserted-by":"crossref","unstructured":"181. \u3000Iwase S, Okamoto T, Mano T, et al. Skin sympathetic outflow in Buerger\u2019s disease. <i>Auton Neurosci<\/i> 2001; 87: 286\u2013292. PMID: 11476291","DOI":"10.1016\/S1566-0702(00)00272-1"},{"key":"183","doi-asserted-by":"crossref","unstructured":"182. \u3000Roncon-Albuquerque R, Serr\u00e3o P, Vale-Pereira R, et al. Plasma catecholamines in Buerger\u2019s disease: Effects of cigarette smoking and surgical sympathectomy. <i>Eur J Vasc Endovasc Surg<\/i> 2002; 24: 338\u2013343. PMID: 12323177","DOI":"10.1053\/ejvs.2002.1721"},{"key":"184","doi-asserted-by":"crossref","unstructured":"183. \u3000Halacheva K, Gulubova MV, Manolova I, et al. Expression of ICAM-1, VCAM-1, E-selectin and TNF-alpha on the endothelium of femoral and iliac arteries in thromboangiitis obliterans. <i>Acta Histochem<\/i> 2002; 104: 177\u2013184. PMID: 12086338","DOI":"10.1078\/0065-1281-00621"},{"key":"185","unstructured":"184. \u3000Pietraszek MH, Choudhury NA, Baba S, et al. Serotonin as a factor involved in pathophysiology of thromboangiitis obliterans. <i>Int Angiol<\/i> 1993; 12: 9\u201312. PMID: 8376917"},{"key":"186","doi-asserted-by":"crossref","unstructured":"185. \u3000Shionoya S. What is Buerger\u2019s disease? <i>World J Surg<\/i> 1983; 7: 544\u2013551. PMID: 6624130","DOI":"10.1007\/BF01655948"},{"key":"187","doi-asserted-by":"crossref","unstructured":"186. \u3000Kim EJ, Cho BS, Lee TS, et al. Morphologic change of the internal elastic lamina in Buerger\u2019s disease. <i>J Korean Med Sci<\/i> 2000; 15: 44\u201348. PMID: 10719807","DOI":"10.3346\/jkms.2000.15.1.44"},{"key":"188","doi-asserted-by":"crossref","unstructured":"187. \u3000Kurata A, Franke FE, Machinami R, et al. Thromboangiitis obliterans: Classic and new morphological features. <i>Virchows Arch<\/i> 2000; 436: 59\u201367. PMID: 10664163","DOI":"10.1007\/PL00008199"},{"key":"189","doi-asserted-by":"crossref","unstructured":"188. \u3000Kurata A, Machinami R, Schulz A, et al. Different immunophenotypes in Buerger\u2019s disease. <i>Pathol Int<\/i> 2003; 53: 608\u2013615. PMID: 14507318","DOI":"10.1046\/j.1440-1827.2003.01528.x"},{"key":"190","unstructured":"189. \u3000Shionoya S. Clinical manifestation in Buerger\u2019s disease. Shionoya S. Buerger\u2019s disease-Pathology, Diagnosis and Treatment. The University of Nagoya Press 1990: 101\u2013117."},{"key":"191","doi-asserted-by":"crossref","unstructured":"190. \u3000Kobayashi M, Nishikimi N, Komori K. Current pathological and clinical aspects of Buerger\u2019s disease in Japan. <i>Ann Vasc Surg<\/i> 2006; 20: 148\u2013156. PMID: 16378138","DOI":"10.1007\/s10016-005-9436-2"},{"key":"192","doi-asserted-by":"crossref","unstructured":"191. \u3000No YJ, Lee EM, Lee DH, et al. Cerebral angiographic findings in thromboangiitis obliterans. <i>Neuroradiology<\/i> 2005; 47: 912\u2013915. PMID: 16133479","DOI":"10.1007\/s00234-005-1445-x"},{"key":"193","doi-asserted-by":"crossref","unstructured":"192. \u3000Becit N, Unl\u00fc Y, Ko\u00e7ak H, et al. Involvement of the coronary artery in a patient with thromboangiitis obliterans. A case report. <i>Heart Vessels<\/i> 2002; 16: 201\u2013203. PMID: 12181595","DOI":"10.1007\/s003800200023"},{"key":"194","doi-asserted-by":"crossref","unstructured":"193. \u3000Donatelli F, Triggiani M, Nascimbene S, et al. Thromboangiitis obliterans of coronary and internal thoracic arteries in a young woman. <i>J Thorac Cardiovasc Surg<\/i> 1997; 113: 800\u2013802. PMID: 9104994","DOI":"10.1016\/S0022-5223(97)70243-5"},{"key":"195","doi-asserted-by":"crossref","unstructured":"194. \u3000Goktas S, Bedir S, Bozlar U, et al. Intrarenal arterial stenosis in a patient with thromboangiitis obliterans. <i>Int J Urol<\/i> 2006; 13: 1243\u20131244. PMID: 16984562","DOI":"10.1111\/j.1442-2042.2006.01546.x"},{"key":"196","doi-asserted-by":"crossref","unstructured":"195. \u3000Kurata A, Nonaka T, Arimura Y, et al. Multiple ulcers with perforation of the small intestine in buerger\u2019s disease: A case report. <i>Gastroenterology<\/i> 2003; 125: 911\u2013916. PMID: 12949735","DOI":"10.1016\/S0016-5085(03)01065-5"},{"key":"197","doi-asserted-by":"crossref","unstructured":"196. \u3000Lee KS, Paik CN, Chung WC, et al. Colon ischemia associated with Buerger\u2019s disease: Case report and review of the literature. <i>Gut Liver<\/i> 2010; 4: 287\u2013291. PMID: 20559539","DOI":"10.5009\/gnl.2010.4.2.287"},{"key":"198","doi-asserted-by":"crossref","unstructured":"197. \u3000Sasaki S, Sakuma M, Kunihara T, et al. Distribution of arterial involvement in thromboangiitis obliterans (Buerger\u2019s disease): Results of a study conducted by the Intractable Vasculitis Syndromes Research Group in Japan. <i>Surg Today<\/i> 2000; 30: 600\u2013605. PMID: 10930225","DOI":"10.1007\/s005950070099"},{"key":"199","unstructured":"198. \u3000Sakaguchi S, Mishima Y. Report of Angiographic Findings. Buerger Disease. Ministry of Health and Welfare Specific Diseases Systematic Study Group on Vascular Lesions Subcommittee Report 1976. 1977: 1\u201338."},{"key":"200","doi-asserted-by":"crossref","unstructured":"199. \u3000Shionoya S, Hirai M, Kawai S, et al. Pattern of arterial occlusion in Buerger\u2019s disease. <i>Angiology<\/i> 1982; 33: 375\u2013384. PMID: 7091768","DOI":"10.1177\/000331978203300603"},{"key":"201","unstructured":"200. \u3000Shionoya S. Buerger\u2019s disease-Pathology, Diagnosis and Treatment. The University of Nagoya Press 1990: 118\u2013150."},{"key":"202","unstructured":"201. \u3000Sakaguchi S, Baba S, Kameda T, et al. Peripheral Circulation Disorders in Collagen Disease \u2014 Arteriography Findings. Ministry of Health and Welfare Specific Diseases Systematic Study Group on Vascular Lesions Subcommittee Report 1976. 1977: 295\u2013302."},{"key":"203","unstructured":"202. \u3000Mishima Y, Kobayashi H, Ohashi S, et al. Disorders of Major Arteries of the Limbs Associated with Collagen Disease \u2014 Arteriography Findings. Ministry of Health and Welfare Specific Diseases Systematic Study Group on Vascular Lesions Subcommittee Report 1976. 1977: 133\u2013136."},{"key":"204","doi-asserted-by":"crossref","unstructured":"203. \u3000Olin JW, Shih A. Thromboangiitis obliterans (Buerger\u2019s disease). <i>Curr Opin Rheumatol<\/i> 2006; 18: 18\u201324. PMID: 16344615","DOI":"10.1097\/01.bor.0000198000.58073.aa"},{"key":"205","doi-asserted-by":"crossref","unstructured":"204. \u3000Mills JL Sr. Buerger\u2019s disease in the 21st century: Diagnosis, clinical features, and therapy. <i>Semin Vasc Surg<\/i> 2003; 16: 179\u2013189. PMID: 12975757","DOI":"10.1016\/S0895-7967(03)00023-1"},{"key":"206","doi-asserted-by":"crossref","unstructured":"205. \u3000Papa MZ, Rabi I, Adar R. A point scoring system for the clinical diagnosis of Buerger\u2019s disease. <i>Eur J Vasc Endovasc Surg<\/i> 1996; 11: 335\u2013339. PMID: 8601245","DOI":"10.1016\/S1078-5884(96)80081-5"},{"key":"207","doi-asserted-by":"crossref","unstructured":"206. \u3000Shionoya S. Buerger\u2019s disease: Diagnosis and management. <i>Cardiovasc Surg<\/i> 1993; 1: 207\u2013214. PMID: 8076031","DOI":"10.1177\/096721099300100302"},{"key":"208","unstructured":"207. \u3000Nakajima N. Buerger\u2019s disease. Health science research project for the control of intractable diseases Study group on intractable vasculitis: Clinical practice manual for intractable vasculitis. 2002: 9\u201312."},{"key":"209","unstructured":"208. \u3000Shigematsu K, Shigematsu H, Yasuda K. Study on intractable vasculitis. Long term prognosis of Buerger disease. Research with (nationwide questionnaire survey results). 2003 Summary and Report of Assigned Studies. 2004: 115\u2013119."},{"key":"210","doi-asserted-by":"crossref","unstructured":"209. \u3000Japanese College of Angiology (ed.) Inter-society consensus for the management of PAD (TASC II). Medical Tribune, Inc. 2007: 44\u201345.","DOI":"10.1016\/j.jvs.2006.12.037"},{"key":"211","doi-asserted-by":"crossref","unstructured":"210. \u3000Saito Y, Sasaki K, Katsuda Y, et al. Effect of autologous bone-marrow cell transplantation on ischemic ulcer in patients with Buerger\u2019s disease. <i>Circ J<\/i> 2007; 71: 1187\u20131192. PMID: 17652879","DOI":"10.1253\/circj.71.1187"},{"key":"212","doi-asserted-by":"crossref","unstructured":"211. \u3000Matoba S, Tatsumi T, Murohara T, et al. TACT Follow-up Study Investigators. Long-term clinical outcome after intramuscular implantation of bone marrow mononuclear cells (Therapeutic Angiogenesis by Cell Transplantation [TACT] trial) in patients with chronic limb ischemia. <i>Am Heart J<\/i> 2008; 156: 1010\u20131018. PMID: 19061721","DOI":"10.1016\/j.ahj.2008.06.025"},{"key":"213","doi-asserted-by":"crossref","unstructured":"212. \u3000Inaba S, Egashira K, Komori K. Peripheral-blood or bone-marrow mononuclear cells for therapeutic angiogenesis? <i>Lancet<\/i> 2002; 360: 2083. PMID: 12504445","DOI":"10.1016\/S0140-6736(02)11976-3"},{"key":"214","unstructured":"213. \u3000Shigematsu H, Shigematsu K. Factors affecting the long-term outcome of Buerger\u2019s disease (thromboangiitis obliterans). <i>Int Angiol<\/i> 1999; 18: 58\u201364. PMID: 10392482"},{"key":"215","doi-asserted-by":"crossref","unstructured":"214. \u3000Sugimoto M, Miyachi H, Morimae H, et al. Fate of ischemic limbs in patients with Buerger\u2019s disease based on our 30-year experience: Does smoking have a definitive impact on the late loss of limbs? <i>Surg Today<\/i> 2015; 45: 466\u2013470. PMID: 24845736","DOI":"10.1007\/s00595-014-0904-6"},{"key":"216","unstructured":"215. \u3000Nakabayashi K. A subcommittee report on epidemiology, prognosis and QOL of medium and small angiitis. Ministry of Health and Welfare Specific Diseases Immunological Diseases Research Group Intractable Vasculitis Subcommittee. 1998 Research Report 1999: 38\u201348."},{"key":"217","unstructured":"216. \u3000Arkin A. A clinical and pathological study of periarteritis nodosa: A report of five cases, one histologically healed. <i>Am J Pathol<\/i> 1930; 6: 401\u2013426.5. PMID: 19969916"},{"key":"218","doi-asserted-by":"crossref","unstructured":"217. \u3000Pagnoux C, Seror R, Henegar C, et al. Clinical features and outcomes in 348 patients with polyarteritis nodosa: A systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French Vasculitis Study Group Database. <i>Arthritis Rheum<\/i> 2010; 62: 616\u2013626. PMID: 20112401","DOI":"10.1002\/art.27240"},{"key":"219","doi-asserted-by":"crossref","unstructured":"218. \u3000Lindberg K. Ein Beitrag zur Kenntnis der periarteriitis nodosa. <i>Acta Med Scand<\/i> 1931; 76: 183\u2013225.","DOI":"10.1111\/j.0954-6820.1931.tb18345.x"},{"key":"220","unstructured":"219. \u3000MHLW health and labour sciences research grant Research project for conquering intractable diseases Study on intractable vasculitides. 2005 Summary and report of assigned studies."},{"key":"221","doi-asserted-by":"crossref","unstructured":"220. \u3000Guillevin L, Cohen P, Mahr A, et al. Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognosis factors: A prospective trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in sixty-five patients. <i>Arthritis Rheum<\/i> 2003; 49: 93\u2013100. PMID: 12579599","DOI":"10.1002\/art.10922"},{"key":"222","doi-asserted-by":"crossref","unstructured":"221. \u3000Guillevin L, Lhote F, Cohen P, et al. Corticosteroids plus pulse cyclophosphamide and plasma exchanges versus corticosteroids plus pulse cyclophosphamide alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome patients with factors predicting poor prognosis. A prospective, randomized trial in sixty-two patients. <i>Arthritis Rheum<\/i> 1995; 38: 1638\u20131645. PMID: 7488285","DOI":"10.1002\/art.1780381116"},{"key":"223","doi-asserted-by":"crossref","unstructured":"222. \u3000Ribi C, Cohen P, Pagnoux C, et al. French Vasculitis Study Group. Treatment of polyarteritis nodosa and microscopic polyangiitis without poor-prognosis factors: A prospective randomized study of one hundred twenty-four patients. <i>Arthritis Rheum<\/i> 2010; 62: 1186\u20131197. PMID: 20131268","DOI":"10.1002\/art.27340"},{"key":"224","unstructured":"223. \u3000Phillip R, Luqmani R. Mortality in systemic vasculitis: A systematic review. <i>Clin Exp Rheumatol<\/i> 2008; 26 Suppl: S94\u2013S104. PMID: 19026150"},{"key":"225","doi-asserted-by":"crossref","unstructured":"224. \u3000Samson M, Pu\u00e9chal X, Devilliers H, et al. French Vasculitis Study Group (FVSG). Long-term follow-up of a randomized trial on 118 patients with polyarteritis nodosa or microscopic polyangiitis without poor-prognosis factors. <i>Autoimmun Rev<\/i> 2014; 13: 197\u2013205. PMID: 24161361","DOI":"10.1016\/j.autrev.2013.10.001"},{"key":"226","doi-asserted-by":"crossref","unstructured":"225. \u3000Guillevin L, Lhote F, Gayraud M, et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. <i>Medicine (Baltimore)<\/i> 1996; 75: 17\u201328. PMID: 8569467","DOI":"10.1097\/00005792-199601000-00003"},{"key":"227","doi-asserted-by":"crossref","unstructured":"226. \u3000Guillevin L, Pagnoux C, Seror R, et al. The Five-Factor Score revisited: Assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. <i>Medicine (Baltimore)<\/i> 2011; 90: 19\u201327. PMID: 21200183","DOI":"10.1097\/MD.0b013e318205a4c6"},{"key":"228","doi-asserted-by":"crossref","unstructured":"227. \u3000Sada KE, Yamamura M, Harigai M, et al. Research Committee on Intractable Vasculitides, the MHLW of Japan. Classification and characteristics of Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis in a nationwide, prospective, inception cohort study. <i>Arthritis Res Ther<\/i> 2014; 16: R101. PMID: 24758294","DOI":"10.1186\/ar4550"},{"key":"229","doi-asserted-by":"crossref","unstructured":"228. \u3000Fujimoto S, Watts RA, Kobayashi S, et al. Comparison of the epidemiology of anti-neutrophil cytoplasmic antibody-associated vasculitis between Japan and the U.K. <i>Rheumatology (Oxford)<\/i> 2011; 50: 1916\u20131920. PMID: 21798892","DOI":"10.1093\/rheumatology\/ker205"},{"key":"230","doi-asserted-by":"crossref","unstructured":"229. \u3000Reinhold-Keller E, Herlyn K, Wagner-Bastmeyer R, et al. Stable incidence of primary systemic vasculitides over five years: Results from the German vasculitis register. <i>Arthritis Rheum<\/i> 2005; 53: 93\u201399. PMID: 15696553","DOI":"10.1002\/art.20928"},{"key":"231","unstructured":"230. \u3000Tsuchiya N, Kobayashi S, Kawasaki A, et al. Genetic background of Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis: Association of HLA-DRB1*0901 with microscopic polyangiitis. <i>J Rheumatol<\/i> 2003; 30: 1534\u20131540. PMID: 12858454"},{"key":"232","unstructured":"231. \u3000Lyons PA, Rayner TF, Trivedi S, et al. Genetically distinct subsets within ANCA-associated vasculitis. <i>N Engl J Med<\/i> 2012; 367: 214\u2013223. PMID: 22808956"},{"key":"233","doi-asserted-by":"crossref","unstructured":"232. \u3000Kessenbrock K, Krumbholz M, Sch\u00f6nermarck U, et al. Netting neutrophils in autoimmune small-vessel vasculitis. <i>Nat Med<\/i> 2009; 15: 623\u2013625. PMID: 19448636","DOI":"10.1038\/nm.1959"},{"key":"234","doi-asserted-by":"crossref","unstructured":"233. \u3000Kawashima S, Arimura Y, Sano K, et al. Immunopathologic co-localization of MPO, IgG, and C3 in glomeruli in human MPO-ANCAassociated glomerulonephritis. <i>Clin Nephrol<\/i> 2013; 79: 292\u2013301. PMID: 23537682","DOI":"10.5414\/CN107675"},{"key":"235","doi-asserted-by":"crossref","unstructured":"234. \u3000Nakazawa D, Tomaru U, Suzuki A, et al. Abnormal conformation and impaired degradation of propylthiouracil-induced neutrophil extracellular traps: Implications of disordered neutrophil extracellular traps in a rat model of myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitis. <i>Arthritis Rheum<\/i> 2012; 64: 3779\u20133787. PMID: 22777766","DOI":"10.1002\/art.34619"},{"key":"236","unstructured":"235. \u3000Supervising editor: Matsuno S, editor: Arimura Y. Guidelines for management of rapidly progressive nephritic syndrome Q&amp;A Revised 2nd edition. Shindan To Chiryo Sha, Inc. 2015: 7."},{"key":"237","unstructured":"236. \u3000Yoshida M, Kobayashi S, Sueishi K, et al. A subcommittee report on the clinics of medium and small vasculitis. Intractable Vasculitis Study Group of the MHLW. Report in 1998. 1999: 239\u2013246."},{"key":"238","doi-asserted-by":"crossref","unstructured":"237. \u3000Watts R, Lane S, Hanslik T, et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. <i>Ann Rheum Dis<\/i> 2007; 66: 222\u2013227. PMID: 16901958","DOI":"10.1136\/ard.2006.054593"},{"key":"239","unstructured":"238. \u3000Policy Research Project for Intractable Diseases funded by Health and Labour Sciences Research Grants (Intractable Diseases Policy Research Project) Study Group on Intractable Vasculitis Arimura Y, Study Group on Intractable Kidney Diseases Maruyama S, Study Group on Diffuse Lung Diseases Honma S. Guidelines for the Management of ANCA-associated Vasculitides 2017. Shindan To Chiryo Sha, Inc. 2017."},{"key":"240","unstructured":"239. \u3000Matsuo S, Kimura K, Arimura Y, et al. Health and labour scientific research \u201cStudy on progressive renal disorders\u201d Subcommittee for the preparation of evidence-based guidelines for management of rapidly progressive glomerulonephritis (RPGN). Evidence-based guidelines for management of rapidly progressive glomerulonephritis (RPGN) 2014. <i>Jpn J Nephrol<\/i> 2015; 57: 139\u2013232."},{"key":"241","doi-asserted-by":"crossref","unstructured":"240. \u3000Mukhtyar C, Flossmann O, Hellmich B, et al. European Vasculitis Study Group (EUVAS). Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: A systematic review by the European League Against Rheumatism systemic vasculitis task force. <i>Ann Rheum Dis<\/i> 2008; 67: 1004\u20131010. PMID: 17911225","DOI":"10.1136\/ard.2007.071936"},{"key":"242","doi-asserted-by":"crossref","unstructured":"241. \u3000Lauque D, Cadranel J, Lazor R, et al. Microscopic polyangiitis with alveolar hemorrhage. A study of 29 cases and review of the literature. Groupe d\u2019Etudes et de Recherche sur les Maladies \u201cOrphelines\u201d Pulmonaires (GERM\u201dO\u201dP). <i>Medicine (Baltimore)<\/i> 2000; 79: 222\u2013233. PMID: 10941351","DOI":"10.1097\/00005792-200007000-00003"},{"key":"243","doi-asserted-by":"crossref","unstructured":"242. \u3000Ozaki S, Atsumi T, Hayashi T, et al. Severity-based treatment for Japanese patients with MPO-ANCA-associated vasculitis: The JMAAV study. <i>Mod Rheumatol<\/i> 2012; 22: 394\u2013404. PMID: 21928092","DOI":"10.3109\/s10165-011-0525-5"},{"key":"244","unstructured":"243. \u3000Wegener F. \u00dcber eine eigenartige rhinogene granulomotose mit besonderer: Beteiligung des arteriensystems und der nieren. <i>Beitr Pathol Anat<\/i> 1939; 102: 36\u201368."},{"key":"245","unstructured":"244. \u3000Japan Rheumatism Foundation Education and Training Committee, Japan College of Rheumatology Lifelong Education Committee. Textbook of Rheumatology revised 2nd edition. Shindan To Chiryo Sha, Inc. 2016."},{"key":"246","doi-asserted-by":"crossref","unstructured":"245. \u3000Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. <i>Arthritis Rheum<\/i> 1994; 37: 187\u2013192. PMID: 8129773","DOI":"10.1002\/art.1780370206"},{"key":"247","doi-asserted-by":"crossref","unstructured":"246. \u3000Csernok E. Anti-neutrophil cytoplasmic antibodies and pathogenesis of small vessel vasculitides. <i>Autoimmun Rev<\/i> 2003; 2: 158\u2013164. PMID: 12848957","DOI":"10.1016\/S1568-9972(03)00010-7"},{"key":"248","unstructured":"247. \u3000Ministry of Health and Welfare Specific Diseases Systematic Study Group on Vascular Lesions. Report in 1998. (Immunological Disease Study Group, Clinical Study Group, funded by a research grant for specific diseases, Ministry of Health and Welfare. Summary Concerning Intractable Vasculitides 1998)"},{"key":"249","unstructured":"248. \u3000Churg J, Strauss L. Allergic granulomatosis, allergic angiitis, and periarteritis nodosa. <i>Am J Pathol<\/i> 1951; 27: 277\u2013301. PMID: 14819261"},{"key":"250","doi-asserted-by":"crossref","unstructured":"249. \u3000Sada KE, Amano K, Uehara R, et al. Research Committee on Intractable Vasculitides, the Ministry of Health, Labour, Welfare of Japan. A nationwide survey on the epidemiology and clinical features of eosinophilic granulomatosis with polyangiitis (Churg-Strauss) in Japan. <i>Mod Rheumatol<\/i> 2014; 24: 640\u2013644. PMID: 24289197","DOI":"10.3109\/14397595.2013.857582"},{"key":"251","doi-asserted-by":"crossref","unstructured":"250. \u3000Gioffredi A, Maritati F, Oliva E, et al. Eosinophilic granulomatosis with polyangiitis: An overview. <i>Front Immunol<\/i> 2014; 5: 549. PMID: 25404930","DOI":"10.3389\/fimmu.2014.00549"},{"key":"252","doi-asserted-by":"crossref","unstructured":"251. \u3000Keogh KA. Leukotriene receptor antagonists and Churg-Strauss syndrome: Cause, trigger or merely an association? <i>Drug Saf<\/i> 2007; 30: 837\u2013843. PMID: 17867722","DOI":"10.2165\/00002018-200730100-00003"},{"key":"253","doi-asserted-by":"crossref","unstructured":"252. \u3000Greco A, Rizzo MI, De Virgilio A, et al. Churg-Strauss syndrome. <i>Autoimmun Rev<\/i> 2015; 14: 341\u2013348. PMID: 25500434","DOI":"10.1016\/j.autrev.2014.12.004"},{"key":"254","doi-asserted-by":"crossref","unstructured":"253. \u3000Vaglio A, Strehl JD, Manger B, et al. IgG4 immune response in Churg-Strauss syndrome. <i>Ann Rheum Dis<\/i> 2012; 71: 390\u2013393. PMID: 22121132","DOI":"10.1136\/ard.2011.155382"},{"key":"255","doi-asserted-by":"crossref","unstructured":"254. \u3000Nagasawa T, Yoshida M. Clinical features of allergic granulomatous angiitis in Japan and the propose of guideline for clinical diagnosis of this disease. <i>J Jpn Soc Intern Med<\/i> 1989; 78: 352\u2013356.","DOI":"10.2169\/naika.78.352"},{"key":"256","unstructured":"255. \u3000Ministry of Health and Welfare Specific Disease Systematic Study Group on Vascular Lesions. 1987 Research Report. 1988."},{"key":"257","doi-asserted-by":"crossref","unstructured":"256. \u3000Feragalli B, Mantini C, Sperandeo M, et al. The lung in systemic vasculitis: Radiological patterns and differential diagnosis. <i>Br J Radiol<\/i> 2016; 89: 20150992. PMID: 26876879","DOI":"10.1259\/bjr.20150992"},{"key":"258","doi-asserted-by":"crossref","unstructured":"257. \u3000Lanham JG, Elkon KB, Pusey CD, et al. Systemic vasculitis with asthma and eosinophilia: A clinical approach to the Churg-Strauss syndrome. <i>Medicine (Baltimore)<\/i> 1984; 63: 65\u201381. PMID: 6366453","DOI":"10.1097\/00005792-198403000-00001"},{"key":"259","doi-asserted-by":"crossref","unstructured":"258. \u3000Masi AT, Hunder GG, Lie JT, et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). <i>Arthritis Rheum<\/i> 1990; 33: 1094\u20131100. PMID: 2202307","DOI":"10.1002\/art.1780330806"},{"key":"260","unstructured":"259. \u3000Ministry of Health and Welfare Specific Diseases Immunological Diseases Study Group Subcommittee on Intractable Vasculitides. 1998 Research Report. 1999."},{"key":"261","doi-asserted-by":"crossref","unstructured":"260. \u3000Groh M, Pagnoux C, Baldini C, et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. <i>Eur J Intern Med<\/i> 2015; 26: 545\u2013553. PMID: 25971154","DOI":"10.1016\/j.ejim.2015.04.022"},{"key":"262","doi-asserted-by":"crossref","unstructured":"261. \u3000Mukhtyar C, Guillevin L, Cid MC, et al. European Vasculitis Study Group. EULAR recommendations for the management of primary small and medium vessel vasculitis. <i>Ann Rheum Dis<\/i> 2009; 68: 310\u2013317. PMID: 18413444","DOI":"10.1136\/ard.2008.088096"},{"key":"263","doi-asserted-by":"crossref","unstructured":"262. \u3000Koyama A, Yamagata K, Makino H, et al. Japan RPGN Registry Group. A nationwide survey of rapidly progressive glomerulonephritis in Japan: Etiology, prognosis and treatment diversity. <i>Clin Exp Nephrol<\/i> 2009; 13: 633\u2013650. PMID: 19533266","DOI":"10.1007\/s10157-009-0201-7"},{"key":"264","doi-asserted-by":"crossref","unstructured":"263. \u3000Netzer KO, Leinonen A, Boutaud A, et al. The goodpasture autoantigen. Mapping the major conformational epitope(s) of alpha3(IV) collagen to residues 17\u201331 and 127\u2013141 of the NC1 domain. <i>J Biol Chem<\/i> 1999; 274: 11267\u201311274. PMID: 10196215","DOI":"10.1074\/jbc.274.16.11267"},{"key":"265","doi-asserted-by":"crossref","unstructured":"264. \u3000Pedchenko V, Bondar O, Fogo AB, et al. Molecular architecture of the Goodpasture autoantigen in anti-GBM nephritis. <i>N Engl J Med<\/i> 2010; 363: 343\u2013354. PMID: 20660402","DOI":"10.1056\/NEJMoa0910500"},{"key":"266","doi-asserted-by":"crossref","unstructured":"265. \u3000Hellmark T, Burkhardt H, Wieslander J. Goodpasture disease. Characterization of a single conformational epitope as the target of pathogenic autoantibodies. <i>J Biol Chem<\/i> 1999; 274: 25862\u201325868. PMID: 10464328","DOI":"10.1074\/jbc.274.36.25862"},{"key":"267","doi-asserted-by":"crossref","unstructured":"266. \u3000Levy JB, Hammad T, Coulthart A, et al. Clinical features and outcome of patients with both ANCA and anti-GBM antibodies. <i>Kidney Int<\/i> 2004; 66: 1535\u20131540. PMID: 15458448","DOI":"10.1111\/j.1523-1755.2004.00917.x"},{"key":"268","doi-asserted-by":"crossref","unstructured":"267. \u3000Jayne DR, Marshall PD, Jones SJ, et al. Autoantibodies to GBM and neutrophil cytoplasm in rapidly progressive glomerulonephritis. <i>Kidney Int<\/i> 1990; 37: 965\u2013970. PMID: 2179617","DOI":"10.1038\/ki.1990.72"},{"key":"269","doi-asserted-by":"crossref","unstructured":"268. \u3000Cui Z, Zhao J, Jia XY, et al. Anti-glomerular basement membrane disease: Outcomes of different therapeutic regimens in a large singlecenter Chinese cohort study. <i>Medicine (Baltimore)<\/i> 2011; 90: 303\u2013311. PMID: 21862934","DOI":"10.1097\/MD.0b013e31822f6f68"},{"key":"270","doi-asserted-by":"crossref","unstructured":"269. \u3000Coombes JS, Fassett RG. Antioxidant therapy in hemodialysis patients: A systematic review. <i>Kidney Int<\/i> 2012; 81: 233\u2013246. PMID: 21975860","DOI":"10.1038\/ki.2011.341"},{"key":"271","doi-asserted-by":"crossref","unstructured":"270. \u3000Davis MD, Brewer JD. Urticarial vasculitis and hypocomplementemic urticarial vasculitis syndrome. <i>Immunol Allergy Clin North Am<\/i> 2004; 24: 183\u2013213, vi. PMID: 15120147","DOI":"10.1016\/j.iac.2004.01.007"},{"key":"272","doi-asserted-by":"crossref","unstructured":"271. \u3000Davis MD, Daoud MS, Kirby B, et al. Clinicopathologic correlation of hypocomplementemic and normocomplementemic urticarial vasculitis. <i>J Am Acad Dermatol<\/i> 1998; 38: 899\u2013905. PMID: 9631995","DOI":"10.1016\/S0190-9622(24)00193-2"},{"key":"273","doi-asserted-by":"crossref","unstructured":"272. \u3000Mehregan DR, Hall MJ, Gibson LE. Urticarial vasculitis: A histopathologic and clinical review of 72 cases. <i>J Am Acad Dermatol<\/i> 1992; 26: 441\u2013448. PMID: 1564151","DOI":"10.1016\/0190-9622(92)70069-R"},{"key":"274","doi-asserted-by":"crossref","unstructured":"273. \u3000Sanchez NP, Winkelmann RK, Schroeter AL, et al. The clinical and histopathologic spectrums of urticarial vasculitis: Study of forty cases. <i>J Am Acad Dermatol<\/i> 1982; 7: 599\u2013605. PMID: 6754776","DOI":"10.1016\/S0190-9622(82)70139-2"},{"key":"275","doi-asserted-by":"crossref","unstructured":"274. \u3000Aydogan K, Karadogan SK, Adim SB, et al. Hypocomplementemic urticarial vasculitis: A rare presentation of systemic lupus erythematosus. <i>Int J Dermatol<\/i> 2006; 45: 1057\u20131061. PMID: 16961508","DOI":"10.1111\/j.1365-4632.2006.02847.x"},{"key":"276","doi-asserted-by":"crossref","unstructured":"275. \u3000Pasini A, Bracaglia C, Aceti A, et al. Renal involvement in hypocomplementaemic urticarial vasculitis syndrome: A report of three paediatric cases. <i>Rheumatology (Oxford)<\/i> 2014; 53: 1409\u20131413. PMID: 24625505","DOI":"10.1093\/rheumatology\/keu023"},{"key":"277","doi-asserted-by":"crossref","unstructured":"276. \u3000Werder M, Truniger B. Hypocomplementaemic urticarial vasculitis. <i>Nephrol Dial Transplant<\/i> 1997; 12: 1278\u20131279. PMID: 9198071","DOI":"10.1093\/ndt\/12.6.1278"},{"key":"278","doi-asserted-by":"crossref","unstructured":"277. \u3000Saadoun D, Sadallah S, Trendelenburg M, et al. Anti-C1q antibodies in hepatitis C virus infection. <i>Clin Exp Immunol<\/i> 2006; 145: 308\u2013312. PMID: 16879251","DOI":"10.1111\/j.1365-2249.2006.03153.x"},{"key":"279","unstructured":"278. \u3000Lienesch DW, Sherman KE, Metzger A, et al. Anti-Clq antibodies in patients with chronic hepatitis C infection. <i>Clin Exp Rheumatol<\/i> 2006; 24: 183\u2013185. PMID: 16762156"},{"key":"280","unstructured":"279. \u3000Wisnieski JJ, Jones SM. IgG autoantibody to the collagen-like region of Clq in hypocomplementemic urticarial vasculitis syndrome, systemic lupus erythematosus, and 6 other musculoskeletal or rheumatic diseases. <i>J Rheumatol<\/i> 1992; 19: 884\u2013888. PMID: 1404125"},{"key":"281","unstructured":"280. \u3000Black AK, Greaves MW. Antihistamines in urticaria and angioedema. <i>Clin Allergy Immunol<\/i> 2002; 17: 249\u2013286. PMID: 12113219"},{"key":"282","doi-asserted-by":"crossref","unstructured":"281. \u3000Black AK. Unusual urticarias. <i>J Dermatol<\/i> 2001; 28: 632\u2013634. PMID: 11770721","DOI":"10.1111\/j.1346-8138.2001.tb00050.x"},{"key":"283","doi-asserted-by":"crossref","unstructured":"282. \u3000Berg RE, Kantor GR, Bergfeld WF. Urticarial vasculitis. <i>Int J Dermatol<\/i> 1988; 27: 468\u2013472. PMID: 3065257","DOI":"10.1111\/j.1365-4362.1988.tb00921.x"},{"key":"284","doi-asserted-by":"crossref","unstructured":"283. \u3000Her MY, Song JY, Kim DY. Hypocomplementemic urticarial vasculitis in systemic lupus erythematosus. <i>J Korean Med Sci<\/i> 2009; 24: 184\u2013186. PMID: 19270838","DOI":"10.3346\/jkms.2009.24.1.184"},{"key":"285","doi-asserted-by":"crossref","unstructured":"284. \u3000Mac\u00eado PA, Garcia CB, Schmitz MK, et al. Juvenile systemic lupus erythematosus and dermatomyositis associated with urticarial vasculitis syndrome: A unique presentation. <i>Rheumatol Int<\/i> 2012; 32: 3643\u20133646. PMID: 20429007","DOI":"10.1007\/s00296-010-1484-4"},{"key":"286","doi-asserted-by":"crossref","unstructured":"285. \u3000Wisnieski JJ. Urticarial vasculitis. <i>Curr Opin Rheumatol<\/i> 2000; 12: 24\u201331. PMID: 10647951","DOI":"10.1097\/00002281-200001000-00005"},{"key":"287","doi-asserted-by":"crossref","unstructured":"286. \u3000Soma J, Sato H, Ito S, et al. Nephrotic syndrome associated with hypocomplementaemic urticarial vasculitis syndrome: Successful treatment with cyclosporin A. <i>Nephrol Dial Transplant<\/i> 1999; 14: 1753\u20131757. PMID: 10435889","DOI":"10.1093\/ndt\/14.7.1753"},{"key":"288","doi-asserted-by":"crossref","unstructured":"287. \u3000Jachiet M, Flageul B, Deroux A, et al. French Vasculitis Study Group. The clinical spectrum and therapeutic management of hypocomplementemic urticarial vasculitis: Data from a French nationwide study of fifty-seven patients. <i>Arthritis Rheumatol<\/i> 2015; 67: 527\u2013534. PMID: 25385679","DOI":"10.1002\/art.38956"},{"key":"289","doi-asserted-by":"crossref","unstructured":"288. \u3000Kartal O, Gulec M, Caliskaner Z, et al. Plasmapheresis in a patient with \u201crefractory\u201d urticarial vasculitis. <i>Allergy Asthma Immunol Res<\/i> 2012; 4: 245\u2013247. PMID: 22754719","DOI":"10.4168\/aair.2012.4.4.245"},{"key":"290","doi-asserted-by":"crossref","unstructured":"289. \u3000Yamazaki-Nakashimada MA, Duran-McKinster C, Ram\u00edrez-Vargas N, et al. Intravenous immunoglobulin therapy for hypocomplementemic urticarial vasculitis associated with systemic lupus erythematosus in a child. <i>Pediatr Dermatol<\/i> 2009; 26: 445\u2013447. PMID: 19689522","DOI":"10.1111\/j.1525-1470.2009.00950.x"},{"key":"291","doi-asserted-by":"crossref","unstructured":"290. \u3000Millns JL, Randle HW, Solley GO, et al. The therapeutic response of urticarial vasculitis to indomethacin. <i>J Am Acad Dermatol<\/i> 1980; 3: 349\u2013355. PMID: 7430455","DOI":"10.1016\/S0190-9622(80)80327-6"},{"key":"292","doi-asserted-by":"crossref","unstructured":"291. \u3000Asherson RA, Buchanan N, Kenwright S, et al. The normocomplementemic urticarial vasculitis syndrome--report of a case and response to colchicine. <i>Clin Exp Dermatol<\/i> 1991; 16: 424\u2013427. PMID: 1806316","DOI":"10.1111\/j.1365-2230.1991.tb01227.x"},{"key":"293","doi-asserted-by":"crossref","unstructured":"292. \u3000Lopez LR, Davis KC, Kohler PF, et al. The hypocomplementemic urticarial-vasculitis syndrome: Therapeutic response to hydroxychloroquine. <i>J Allergy Clin Immunol<\/i> 1984; 73: 600\u2013603. PMID: 6371104","DOI":"10.1016\/0091-6749(84)90518-9"},{"key":"294","doi-asserted-by":"crossref","unstructured":"293. \u3000Ruzicka T, Goerz G. Systemic lupus erythematosus and vasculitic urticaria. Effect of dapsone and complement levels. <i>Dermatologica<\/i> 1981; 162: 203\u2013205. PMID: 7250465","DOI":"10.1159\/000250270"},{"key":"295","unstructured":"294. \u3000Holtman JH, Neustadt DH, Klein J, et al. Dapsone is an effective therapy for the skin lesions of subacute cutaneous lupus erythematosus and urticarial vasculitis in a patient with C2 deficiency. <i>J Rheumatol<\/i> 1990; 17: 1222\u20131225. PMID: 2290166"},{"key":"296","unstructured":"295. \u3000Takahashi K, Oharaseki T, Yokouchi Y, et al. New classification of vasculitides: 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides (CHCC2012). <i>Jpn J Nephrol<\/i> 2014; 56: 70\u201379."},{"key":"297","doi-asserted-by":"crossref","unstructured":"296. \u3000Saulsbury FT. Henoch-Sch\u00f6nlein purpura in children. Report of 100 patients and review of the literature. <i>Medicine (Baltimore)<\/i> 1999; 78: 395\u2013409. PMID: 10575422","DOI":"10.1097\/00005792-199911000-00005"},{"key":"298","unstructured":"297. \u3000Guidelines for the diagnosis and treatment of cardiovascular diseases. Guidelines for management of vasculitis syndrome. <i>Circ J<\/i> 2008; 72 Suppl IV: 1303\u20131305. http:\/\/www.j-circ.or.jp\/guideline\/pdf\/JCS2008_ozaki_h.pdf"},{"key":"299","doi-asserted-by":"crossref","unstructured":"298. \u3000Mills JA, Michel BA, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of Henoch-Sch\u00f6nlein purpura. <i>Arthritis Rheum<\/i> 1990; 33: 1114\u20131121. PMID: 2202310","DOI":"10.1002\/art.1780330809"},{"key":"300","unstructured":"299. \u3000Japan Intractable Diseases Information Center. Purpura nephritis (designated intractable disease 224). http:\/\/www.nanbyou.or.jp\/entry\/4658"},{"key":"301","doi-asserted-by":"crossref","unstructured":"300. \u3000Counahan R, Winterborn MH, White RH, et al. Prognosis of Henoch-Sch\u00f6nlein nephritis in children. <i>Br Med J<\/i> 1977; 2: 11\u201314. PMID: 871734","DOI":"10.1136\/bmj.2.6078.11"},{"key":"302","doi-asserted-by":"crossref","unstructured":"301. \u3000Ronkainen J, Koskimies O, Ala-Houhala M, et al. Early prednisone therapy in Henoch-Sch\u00f6nlein purpura: A randomized, double-blind, placebo-controlled trial. <i>J Pediatr<\/i> 2006; 149: 241\u2013247. PMID: 16887443","DOI":"10.1016\/j.jpeds.2006.03.024"},{"key":"303","doi-asserted-by":"crossref","unstructured":"302. \u3000Shin JI, Park JM, Shin YH, et al. Predictive factors for nephritis, relapse, and significant proteinuria in childhood Henoch-Sch\u00f6nlein purpura. <i>Scand J Rheumatol<\/i> 2006; 35: 56\u201360. PMID: 16467044","DOI":"10.1080\/03009740510026841"},{"key":"304","unstructured":"303. \u3000Dudley J, Smith G, Llewelyn-Edwards A, et al. Randomised, double-blind, placebo-controlled trial to determine whether steroids reduce the incidence and severity of nephropathy in Henoch-Schonlein Purpura (HSP). <i>Arch Dis Child<\/i> 2013; 98: 756\u2013763. PMID: 23845696"},{"key":"305","doi-asserted-by":"crossref","unstructured":"304. \u3000Hahn D, Hodson EM, Willis NS, et al. Interventions for preventing and treating kidney disease in Henoch-Sch\u00f6nlein Purpura (HSP). <i>Cochrane Database Syst Rev<\/i>2015: CD005128. PMID: 26258874","DOI":"10.1002\/14651858.CD005128.pub3"},{"key":"306","unstructured":"305. \u3000Hong S, Ahn SM, Lim DH, et al. Late-onset IgA vasculitis in adult patients exhibits distinct clinical characteristics and outcomes. <i>Clin Exp Rheumatol<\/i> 2016; 34 Suppl: S77\u2013S83. PMID: 26842218"},{"key":"307","doi-asserted-by":"crossref","unstructured":"306. \u3000Chapter 11: Henoch-Sch\u00f6nlein purpura nephritis. <i>Kidney Int Suppl<\/i> 2012; 2: 218\u2013220. PMID: 25018936","DOI":"10.1038\/kisup.2012.24"},{"key":"308","doi-asserted-by":"crossref","unstructured":"307. \u3000Kawasaki Y, Suzuki J, Suzuki H. Efficacy of methylprednisolone and urokinase pulse therapy combined with or without cyclophosphamide in severe Henoch-Schoenlein nephritis: A clinical and histopathological study. <i>Nephrol Dial Transplant<\/i> 2004; 19: 858\u2013864. PMID: 15031341","DOI":"10.1093\/ndt\/gfg617"},{"key":"309","unstructured":"308. \u3000Bergstein J, Leiser J, Andreoli SP. Response of crescentic Henoch-Schoenlein purpura nephritis to corticosteroid and azathioprine therapy. <i>Clin Nephrol<\/i> 1998; 49: 9\u201314. PMID: 9491279"},{"key":"310","doi-asserted-by":"crossref","unstructured":"309. \u3000Foster BJ, Bernard C, Drummond KN, et al. Effective therapy for severe Henoch-Schonlein purpura nephritis with prednisone and azathioprine: A clinical and histopathologic study. <i>J Pediatr<\/i> 2000; 136: 370\u2013375. PMID: 10700695","DOI":"10.1067\/mpd.2000.103448"},{"key":"311","doi-asserted-by":"crossref","unstructured":"310. \u3000Du Y, Hou L, Zhao C, et al. Treatment of children with Henoch-Sch\u00f6nlein purpura nephritis with mycophenolate mofetil. <i>Pediatr Nephrol<\/i> 2012; 27: 765\u2013771. PMID: 22081165","DOI":"10.1007\/s00467-011-2057-9"},{"key":"312","doi-asserted-by":"crossref","unstructured":"311. \u3000Ren P, Han F, Chen L, et al. The combination of mycophenolate mofetil with corticosteroids induces remission of Henoch-Sch\u00f6nlein purpura nephritis. <i>Am J Nephrol<\/i> 2012; 36: 271\u2013277. PMID: 22965140","DOI":"10.1159\/000341914"},{"key":"313","doi-asserted-by":"crossref","unstructured":"312. \u3000Jauhola O, Ronkainen J, Autio-Harmainen H, et al. Cyclosporine A vs. methylprednisolone for Henoch-Sch\u00f6nlein nephritis: A randomized trial. <i>Pediatr Nephrol<\/i> 2011; 26: 2159\u20132166. PMID: 21626222","DOI":"10.1007\/s00467-011-1919-5"},{"key":"314","doi-asserted-by":"crossref","unstructured":"313. \u3000Park JM, Won SC, Shin JI, et al. Cyclosporin A therapy for Henoch-Sch\u00f6nlein nephritis with nephrotic-range proteinuria. <i>Pediatr Nephrol<\/i> 2011; 26: 411\u2013417. PMID: 21184240","DOI":"10.1007\/s00467-010-1723-7"},{"key":"315","doi-asserted-by":"crossref","unstructured":"314. \u3000Hattori M, Ito K, Konomoto T, et al. Plasmapheresis as the sole therapy for rapidly progressive Henoch-Sch\u00f6nlein purpura nephritis in children. <i>Am J Kidney Dis<\/i> 1999; 33: 427\u2013433. PMID: 10070905","DOI":"10.1016\/S0272-6386(99)70178-2"},{"key":"316","doi-asserted-by":"crossref","unstructured":"315. \u3000Kawasaki Y, Suzuki J, Murai M, et al. Plasmapheresis therapy for rapidly progressive Henoch-Sch\u00f6nlein nephritis. <i>Pediatr Nephrol<\/i> 2004; 19: 920\u2013923. PMID: 15197640","DOI":"10.1007\/s00467-004-1514-0"},{"key":"317","doi-asserted-by":"crossref","unstructured":"316. \u3000Tarshish P, Bernstein J, Edelmann CM Jr. Henoch-Sch\u00f6nlein purpura nephritis: Course of disease and efficacy of cyclophosphamide. <i>Pediatr Nephrol<\/i> 2004; 19: 51\u201356. PMID: 14634864","DOI":"10.1007\/s00467-003-1315-x"},{"key":"318","doi-asserted-by":"crossref","unstructured":"317. \u3000Pillebout E, Alberti C, Guillevin L, et al. CESAR study group. Addition of cyclophosphamide to steroids provides no benefit compared with steroids alone in treating adult patients with severe Henoch Sch\u00f6nlein Purpura. <i>Kidney Int<\/i> 2010; 78: 495\u2013502. PMID: 20505654","DOI":"10.1038\/ki.2010.150"},{"key":"319","doi-asserted-by":"crossref","unstructured":"318. \u3000Kanai H, Sawanobori E, Kobayashi A, et al. Early treatment with methylprednisolone pulse therapy combined with tonsillectomy for heavy proteinuric henoch-sch\u00f6nlein purpura nephritis in children. <i>Nephron Extra<\/i> 2011; 1: 101\u2013111. PMID: 22470384","DOI":"10.1159\/000333010"},{"key":"320","doi-asserted-by":"crossref","unstructured":"319. \u3000Lamprecht P, Gause A, Gross WL. Cryoglobulinemic vasculitis. <i>Arthritis Rheum<\/i> 1999; 42: 2507\u20132516. PMID: 10615995","DOI":"10.1002\/1529-0131(199912)42:12<2507::AID-ANR2>3.0.CO;2-#"},{"key":"321","doi-asserted-by":"crossref","unstructured":"320. \u3000Garc\u00eda-Carrasco M, Ramos-Casals M, Cervera R, et al. Cryoglobulinemia in systemic lupus erythematosus: Prevalence and clinical characteristics in a series of 122 patients. <i>Semin Arthritis Rheum<\/i> 2001; 30: 366\u2013373. PMID: 11303309","DOI":"10.1053\/sarh.2001.20265"},{"key":"322","doi-asserted-by":"crossref","unstructured":"321. \u3000Ramos-Casals M, Cervera R, Yag\u00fce J, et al. Cryoglobulinemia in primary Sj\u00f6gren\u2019s syndrome: Prevalence and clinical characteristics in a series of 115 patients. <i>Semin Arthritis Rheum<\/i> 1998; 28: 200\u2013205. PMID: 9872481","DOI":"10.1016\/S0049-0172(98)80037-1"},{"key":"323","doi-asserted-by":"crossref","unstructured":"322. \u3000Cicardi M, Cesana B, Del Ninno E, et al. Prevalence and risk factors for the presence of serum cryoglobulins in patients with chronic hepatitis C. <i>J Viral Hepat<\/i> 2000; 7: 138\u2013143. PMID: 10760044","DOI":"10.1046\/j.1365-2893.2000.00204.x"},{"key":"324","doi-asserted-by":"crossref","unstructured":"323. \u3000Ramos-Casals M, Mu\u00f1oz S, Medina F, et al. HISPAMEC Study Group. Systemic autoimmune diseases in patients with hepatitis C virus infection: Characterization of 1020 cases (The HISPAMEC Registry). <i>J Rheumatol<\/i> 2009; 36: 1442\u20131448. PMID: 19369460","DOI":"10.3899\/jrheum.080874"},{"key":"325","doi-asserted-by":"crossref","unstructured":"324. \u3000Brouet JC, Clauvel JP, Danon F, et al. Biologic and clinical significance of cryoglobulins: A report of 86 cases. <i>Am J Med<\/i> 1974; 57: 775\u2013788. PMID: 4216269","DOI":"10.1016\/0002-9343(74)90852-3"},{"key":"326","doi-asserted-by":"crossref","unstructured":"325. \u3000Motyckova G, Murali M. Laboratory testing for cryoglobulins. <i>Am J Hematol<\/i> 2011; 86: 500\u2013502. PMID: 21594887","DOI":"10.1002\/ajh.22023"},{"key":"327","doi-asserted-by":"crossref","unstructured":"326. \u3000Trejo O, Ramos-Casals M, Garc\u00eda-Carrasco M, et al. Cryoglobulinemia: Study of etiologic factors and clinical and immunologic features in 443 patients from a single center. <i>Medicine (Baltimore)<\/i> 2001; 80: 252\u2013262. PMID: 11470986","DOI":"10.1097\/00005792-200107000-00004"},{"key":"328","doi-asserted-by":"crossref","unstructured":"327. \u3000Terrier B, Carrat F, Krastinova E, et al. Prognostic factors of survival in patients with non-infectious mixed cryoglobulinaemia vasculitis: Data from 242 cases included in the CryoVas survey. <i>Ann Rheum Dis<\/i> 2013; 72: 374\u2013380. PMID: 22586172","DOI":"10.1136\/annrheumdis-2012-201405"},{"key":"329","doi-asserted-by":"crossref","unstructured":"328. \u3000De Vita S, Soldano F, Isola M, et al. Preliminary classification criteria for the cryoglobulinaemic vasculitis. <i>Ann Rheum Dis<\/i> 2011; 70: 1183\u20131190. PMID: 21571735","DOI":"10.1136\/ard.2011.150755"},{"key":"330","doi-asserted-by":"crossref","unstructured":"329. \u3000Dammacco F, Sansonno D. Therapy for hepatitis C virus-related cryoglobulinemic vasculitis. <i>N Engl J Med<\/i> 2013; 369: 1035\u20131045. PMID: 24024840","DOI":"10.1056\/NEJMra1208642"},{"key":"331","doi-asserted-by":"crossref","unstructured":"330. \u3000Pietrogrande M, De Vita S, Zignego AL, et al. Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients. <i>Autoimmun Rev<\/i> 2011; 10: 444\u2013454. PMID: 21303705","DOI":"10.1016\/j.autrev.2011.01.008"},{"key":"332","doi-asserted-by":"crossref","unstructured":"331. \u3000De Vita S, Quartuccio L, Isola M, et al. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. <i>Arthritis Rheum<\/i> 2012; 64: 843\u2013853. PMID: 22147661","DOI":"10.1002\/art.34331"},{"key":"333","doi-asserted-by":"crossref","unstructured":"332. \u3000Saadoun D, Resche Rigon M, Sene D, et al. Rituximab plus Peginterferon-alpha\/ribavirin compared with Peg-interferon-alpha\/ribavirin in hepatitis C-related mixed cryoglobulinemia. <i>Blood<\/i> 2010; 116: 326\u2013334. PMID: 20439619","DOI":"10.1182\/blood-2009-10-248518"},{"key":"334","doi-asserted-by":"crossref","unstructured":"333. \u3000Ferri C, Cacoub P, Mazzaro C, et al. Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: Results of multicenter cohort study and review of the literature. <i>Autoimmun Rev<\/i> 2011; 11: 48\u201355. PMID: 21821153","DOI":"10.1016\/j.autrev.2011.07.005"},{"key":"335","doi-asserted-by":"crossref","unstructured":"334. \u3000Ramos-Casals M, Robles A, Brito-Zer\u00f3n P, et al. Life-threatening cryoglobulinemia: Clinical and immunological characterization of 29 cases. <i>Semin Arthritis Rheum<\/i> 2006; 36: 189\u2013196. PMID: 16996578","DOI":"10.1016\/j.semarthrit.2006.08.005"},{"key":"336","doi-asserted-by":"crossref","unstructured":"335. \u3000Sakane T, Takeno M, Suzuki N, et al. Beh\u00e7et\u2019s disease. <i>N Engl J Med<\/i> 1999; 341: 1284\u20131291. PMID: 10528040","DOI":"10.1056\/NEJM199910213411707"},{"key":"337","doi-asserted-by":"crossref","unstructured":"336. \u3000Takeno M, Ideguchi H, Suda A, et al. Vascular involvement of Beh\u00e7et\u2019s disease.<i>In<\/i>: Ishigatsubo Y, editor. Beh\u00e7et\u2019s disease. Springer, 2015: 79\u2013100.","DOI":"10.1007\/978-4-431-54487-6_5"},{"key":"338","unstructured":"337. \u3000Japan Intractable Diseases Information Center. Beh\u00e7et\u2019s disease (designated intractable disease 56). http:\/\/www.nanbyou.or.jp\/entry\/330"},{"key":"339","doi-asserted-by":"crossref","unstructured":"338. \u3000Seyahi E, Caglar E, Ugurlu S, et al. An outcome survey of 43 patients with Budd-Chiari syndrome due to Beh\u00e7et\u2019s syndrome followed up at a single, dedicated center. <i>Semin Arthritis Rheum<\/i> 2015; 44: 602\u2013609. PMID: 25476470","DOI":"10.1016\/j.semarthrit.2014.10.014"},{"key":"340","doi-asserted-by":"crossref","unstructured":"339. \u3000Saadoun D, Asli B, Wechsler B, et al. Long-term outcome of arterial lesions in Beh\u00e7et disease: A series of 101 patients. <i>Medicine (Baltimore)<\/i> 2012; 91: 18\u201324. PMID: 22198498","DOI":"10.1097\/MD.0b013e3182428126"},{"key":"341","doi-asserted-by":"crossref","unstructured":"340. \u3000T\u00fcz\u00fcn H, Be\u015firli K, Sayin A, et al. Management of aneurysms in Beh\u00e7et\u2019s syndrome: An analysis of 24 patients. <i>Surgery<\/i> 1997; 121: 150\u2013156. PMID: 9037226","DOI":"10.1016\/S0039-6060(97)90284-1"},{"key":"342","doi-asserted-by":"crossref","unstructured":"341. \u3000Seyahi E, Melikoglu M, Akman C, et al. Pulmonary artery involvement and associated lung disease in Beh\u00e7et disease: A series of 47 patients. <i>Medicine (Baltimore)<\/i> 2012; 91: 35\u201348. PMID: 22210555","DOI":"10.1097\/MD.0b013e318242ff37"},{"key":"343","unstructured":"342. \u3000International Study Group for Beh\u00e7et\u2019s Disease. Criteria for diagnosis of Beh\u00e7et\u2019s disease. <i>Lancet<\/i> 1990; 335: 1078\u20131080. PMID: 1970380"},{"key":"344","doi-asserted-by":"crossref","unstructured":"343. \u3000Davatchi F. International Team for the Revision of the International Criteria for Beh\u00e7et\u2019s Disease (ITR-ICBD). The International Criteria for Beh\u00e7et\u2019s Disease (ICBD): A collaborative study of 27 countries on the sensitivity and specificity of the new criteria. <i>J Eur Acad Dermatol Venereol<\/i> 2014; 28: 338\u2013347. PMID: 23441863","DOI":"10.1111\/jdv.12107"},{"key":"345","doi-asserted-by":"crossref","unstructured":"344. \u3000Ahn JK, Lee YS, Jeon CH, et al. Treatment of venous thrombosis associated with Behcet\u2019s disease: Immunosuppressive therapy alone versus immunosuppressive therapy plus anticoagulation. <i>Clin Rheumatol<\/i> 2008; 27: 201\u2013205. PMID: 17636362","DOI":"10.1007\/s10067-007-0685-z"},{"key":"346","doi-asserted-by":"crossref","unstructured":"345. \u3000Desbois AC, Wechsler B, Resche-Rigon M, et al. Immunosuppressants reduce venous thrombosis relapse in Beh\u00e7et\u2019s disease. <i>Arthritis Rheum<\/i> 2012; 64: 2753\u20132760. PMID: 22354392","DOI":"10.1002\/art.34450"},{"key":"347","doi-asserted-by":"crossref","unstructured":"346. \u3000Alibaz-Oner F, Karadeniz A, Ylmaz S, et al. Beh\u00e7et disease with vascular involvement: Effects of different therapeutic regimens on the incidence of new relapses. <i>Medicine (Baltimore)<\/i> 2015; 94: e494. PMID: 25674739","DOI":"10.1097\/MD.0000000000000494"},{"key":"348","doi-asserted-by":"crossref","unstructured":"347. \u3000Mehta P, Laffan M, Haskard DO. Thrombosis and Beh\u00e7et\u2019s syndrome in non-endemic regions. <i>Rheumatology (Oxford)<\/i> 2010; 49: 2003\u20132004. PMID: 20421214","DOI":"10.1093\/rheumatology\/keq090"},{"key":"349","unstructured":"348. \u3000Ha YJ, Jung SY, Lee KH, et al. Long-term clinical outcomes and risk factors for the occurrence of post-operative complications after cardiovascular surgery in patients with Beh\u00e7et\u2019s disease. <i>Clin Exp Rheumatol<\/i> 2012; 30 Suppl: S18\u2013S26. PMID: 22776346"},{"key":"350","doi-asserted-by":"crossref","unstructured":"349. \u3000Tuzun H, Seyahi E, Arslan C, et al. Management and prognosis of nonpulmonary large arterial disease in patients with Beh\u00e7et disease. <i>J Vasc Surg<\/i> 2012; 55: 157\u2013163. PMID: 21944910","DOI":"10.1016\/j.jvs.2011.07.049"},{"key":"351","doi-asserted-by":"crossref","unstructured":"350. \u3000Kim WH, Choi D, Kim JS, et al. Effectiveness and safety of endovascular aneurysm treatment in patients with vasculo-Beh\u00e7et disease. <i>J Endovasc Ther<\/i> 2009; 16: 631\u2013636. PMID: 19842735","DOI":"10.1583\/09-2812.1"},{"key":"352","doi-asserted-by":"crossref","unstructured":"351. \u3000Yang SS, Park KM, Park YJ, et al. Peripheral arterial involvement in Behcet\u2019s disease: An analysis of the results from a Korean referral center. <i>Rheumatol Int<\/i> 2013; 33: 2101\u20132108. PMID: 23417141","DOI":"10.1007\/s00296-013-2700-9"},{"key":"353","doi-asserted-by":"crossref","unstructured":"352. \u3000Liu Q, Ye W, Liu C, et al. Outcomes of vascular intervention and use of perioperative medications for nonpulmonary aneurysms in Beh\u00e7et disease. <i>Surgery<\/i> 2016; 159: 1422\u20131429. PMID: 26765098","DOI":"10.1016\/j.surg.2015.11.022"},{"key":"354","doi-asserted-by":"crossref","unstructured":"353. \u3000Saadoun D, Wechsler B, Desseaux K, et al. Mortality in Beh\u00e7et\u2019s disease. <i>Arthritis Rheum<\/i> 2010; 62: 2806\u20132812. PMID: 20496419","DOI":"10.1002\/art.27568"},{"key":"355","unstructured":"354. \u3000Hashimoto H, et al. Revised diagnostic criteria and guidelines for treatment of malignant rheumatoid arthritis (draft). MRA subcommittee, MHLW Specified Diseases Systematic Study Group on Vascular Lesions. 1987 Research Report. 1988: 23\u201325."},{"key":"356","doi-asserted-by":"crossref","unstructured":"355. \u3000Ntatsaki E, Mooney J, Scott DG, et al. Systemic rheumatoid vasculitis in the era of modern immunosuppressive therapy. <i>Rheumatology (Oxford)<\/i> 2014; 53: 145\u2013152. PMID: 24108586","DOI":"10.1093\/rheumatology\/ket326"},{"key":"357","doi-asserted-by":"crossref","unstructured":"356. \u3000Turesson C, Schaid DJ, Weyand CM, et al. Association of HLA-C3 and smoking with vasculitis in patients with rheumatoid arthritis. <i>Arthritis Rheum<\/i> 2006; 54: 2776\u20132783. PMID: 16947780","DOI":"10.1002\/art.22057"},{"key":"358","doi-asserted-by":"crossref","unstructured":"357. \u3000Scott DG, Bacon PA, Tribe CR. Systemic rheumatoid vasculitis: A clinical and laboratory study of 50 cases. <i>Medicine (Baltimore)<\/i> 1981; 60: 288\u2013297. PMID: 7242322","DOI":"10.1097\/00005792-198107000-00004"},{"key":"359","unstructured":"358. \u3000MHLW of Japan. Malignant Rheumatoid Arthritis. Summary, Diagnostic Criteria, etc. Intractable diseases designated on January 1, 2015 (newly designated, updated). http:\/\/www.mhlw.go.jp\/stf\/seisakunitsuite\/bunya\/0000062437.html"},{"key":"360","doi-asserted-by":"crossref","unstructured":"359. \u3000Heurkens AH, Westedt ML, Breedveld FC. Prednisone plus azathioprine treatment in patients with rheumatoid arthritis complicated by vasculitis. <i>Arch Intern Med<\/i> 1991; 151: 2249\u20132254. PMID: 1953230","DOI":"10.1001\/archinte.151.11.2249"},{"key":"361","doi-asserted-by":"crossref","unstructured":"360. \u3000Bartels CM, Bridges AJ. Rheumatoid vasculitis: Vanishing menace or target for new treatments? <i>Curr Rheumatol Rep<\/i> 2010; 12: 414\u2013419. PMID: 20842467","DOI":"10.1007\/s11926-010-0130-1"},{"key":"362","doi-asserted-by":"crossref","unstructured":"361. \u3000Saint Marcoux B, De Bandt M. CRI (Club Rhumatismes et Inflammation). Vasculitides induced by TNFalpha antagonists: A study in 39 patients in France. <i>Joint Bone Spine<\/i> 2006; 73: 710\u2013713. PMID: 17127088","DOI":"10.1016\/j.jbspin.2006.02.010"},{"key":"363","doi-asserted-by":"crossref","unstructured":"362. \u3000Sokumbi O, Wetter DA, Makol A, et al. Vasculitis associated with tumor necrosis factor-\u03b1 inhibitors. <i>Mayo Clin Proc<\/i> 2012; 87: 739\u2013745. PMID: 22795634","DOI":"10.1016\/j.mayocp.2012.04.011"},{"key":"364","unstructured":"363. \u3000Mohan N, Edwards ET, Cupps TR, et al. Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents. <i>J Rheumatol<\/i> 2004; 31: 1955\u20131958. PMID: 15468359"},{"key":"365","doi-asserted-by":"crossref","unstructured":"364. \u3000Kim MJ, Kim HO, Kim HY, et al. Rituximab-induced vasculitis: A case report and review of the medical published work. <i>J Dermatol<\/i> 2009; 36: 284\u2013287. PMID: 19382999","DOI":"10.1111\/j.1346-8138.2009.00639.x"},{"key":"366","doi-asserted-by":"crossref","unstructured":"365. \u3000Carvajal Alegria G, Uguen A, Genestet S, et al. New onset of rheumatoid vasculitis during abatacept therapy and subsequent improvement after rituximab. <i>Joint Bone Spine<\/i> 2016; 83: 605\u2013606. PMID: 27052429","DOI":"10.1016\/j.jbspin.2015.08.016"},{"key":"367","doi-asserted-by":"crossref","unstructured":"366. \u3000Katz-Agranov N, Khattri S, Zandman-Goddard G. The role of intravenous immunoglobulins in the treatment of rheumatoid arthritis. <i>Autoimmun Rev<\/i> 2015; 14: 651\u2013658. PMID: 25870941","DOI":"10.1016\/j.autrev.2015.04.003"},{"key":"368","unstructured":"367. \u3000MHLW Health Service Bureau, Study group on the management of intractable diseases. Summary of measures against intractable diseases. 2007 edition. Taiyou Bijutsu Co., Ltd. 2007: 318."}],"container-title":["Circulation Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/84\/2\/84_CJ-19-0773\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T04:47:47Z","timestamp":1722314867000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/84\/2\/84_CJ-19-0773\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,24]]},"references-count":368,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1253\/circj.cj-19-0773","relation":{},"ISSN":["1346-9843","1347-4820"],"issn-type":[{"value":"1346-9843","type":"print"},{"value":"1347-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,24]]}}}